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 The body’s humoral immune response plays a larger role in the body’s defenses 
beyond screening for invading pathogens. Modulation of this response is also vital for 
tissue regeneration, drug delivery, and vaccine development. The immune system 
operates within a complicated feedback loop and as such, altering the strength of the 
immune response can be approached from an engineering perspective. While a strong 
initial input can direct the response to either a pro- or anti-inflammatory bias, extreme 
responses can be deleterious, as in the case of allergic reactions or sepsis. Therefore, the 
objective of this thesis was to develop a novel biomaterials platform that can be used to 
alter the immune response in a tunable manner.  
 Antibodies are not only produced as a product of the adaptive immune response 
but are also powerful immunomodulators of the innate immune response through the 
activity of their Fc regions. Therefore, the overall hypothesis of this work was that 
coating microparticles with Fc ligands in variable surface densities would modify the 
input signal so that the immune response can be directed. Microparticle size was also 
investigated as a system variable to decouple the effects of physical versus metabolic 
signaling. The goal of this thesis was to analyze the effects of Fc coated particles on two 
major components of the humoral immune responses: macrophages and the complement 
system. The biophysical response of macrophage phagocytosis was evaluated; both Fc 
density and microparticle size had significant impacts on macrophage phagocytosis. 
Smaller microparticles (0.5 μm and 1 μm) coated with a high Fc density resulted in the 
greatest average number of particles per cell. However the larger microparticles (3 μm 
and 4.5 μm) resulted in fewer particles internalized but the greatest internalized volume 
 xx 
of particles per cell. These results provide a particle delivery “toolbox” for future 
applications involving phagocytosis by macrophages. The downstream effects of Fc 
particles on macrophage phenotype and phenotype plasticity were also analyzed. 
Results showed that gene expression varied in an Fc-density dependent manner, and 
that the addition of Fc coated particles can invert the response of LPS and IL-4 treated 
macrophages. When developed, these results are likely to have broader implications in 
the tissue regeneration and biomaterials fields. 
 The effects of the Fc coated particles were also tested in the context of the 
complement system, an often overlooked cascade of protein activation that results in cell 
opsonization and lysis. Cleaved components of the complement system are also powerful 
chemokines as they act as chemoattractants and may play an important role in vaccine 
adjuvants. The smaller particles of 0.5 μm and 1 μm resulted in the greatest levels of 
complement system activation. Fc density played a significant role in complement system 
activation, both through the classical and alternative pathway. It was observed that 
modifying density led to a binary response for smaller particles and a tunable response 
for larger particles. These results were tested in vitro by using Fc particles as a new form 
of antibiotic to direct complement-mediated bacterial cytotoxicity. Finally, Fc coated 
microparticles were then tested as an adjuvant in an attempt to better understand and 
improve the tuberculosis vaccine. These findings are significant to both the biomaterials 
and the larger immunology fields: it was observed that Fc microparticles can be used to 
tunably activate a wide range of immune processes, and could be used both to answer 




CHAPTER 1  INTRODUCTION  
 The immune response represents a complicated and multi-facetted challenge, as it 
is a complex system operating within a series of layered feedback loops. Functionalized 
microparticles offer an opportunity to tune the outputs of these systems through simple 
adjustment of system variables, such as particle size, material properties, and surface 
coating. It has long been understood that the Fc region of an antibody is an important 
opsonin and immune activator. Fully understanding the effect of microparticle size and 
Fc density on the humoral immune response will answer fundamental questions in 
immunology. This will also allow future researchers to apply these results to a broad 
range of immunological disorders and biomaterials applications. 
1.1 Motivation 
 The immune system plays a large role in a variety of pathological disorders, 
would healing, tissue regeneration, and infectious diseases. In many of these cases, 
modulating or controlling the immune response is an important facet of treatment. [1-9]  
However, when trying to control the immune system, it must be kept in mind that 
directing the response to a strong pro- or anti-inflammatory bias can be detrimental. In 
the case of autoimmune disorders, completely diminishing the immune response leaves 
the patient open to secondary infections. Over-stimulating the immune response can lead 
to tissue damage or anaphylaxis. For example, it has been shown that complement system 
components deposited on red blood cells can help mask incompatible antigens to prevent 
rejection in blood transfusions, but too much complement system activation will lead to 
red blood cell lysis. [10] Complement system activation has also been shown to increase 
the efficacy of vaccines as an alternative to traditional adjuvants, however this work is 
still in early research stages. [11-13] These are just a few examples that highlight the 
importance of having a platform capable of modulating the immune response.  
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 There is also a significant need to better understand and control macrophage 
responses, to fully take advantage of their broad capabilities and phenotypic capacities. 
[1, 14-17] For example, research has shown that delivering anti-inflammatory activated 
macrophages to the site of spinal cord injury can lead to increased nerve regeneration 
while pro-inflammatory macrophages are detrimental. [18] A simple reagent that could 
be used to inhibit the inflammatory phenotype would therefore be of tremendous value to 
tissue regeneration efforts. As another example, Mycobacterium tuberculosis targets and 
reproduces within alveolar macrophages. Over 2 billion people have been infected with 
M. tuberculosis in recorded history, and there are over 8 million new cases each year 
resulting in 1.5 million deaths. M. tuberculosis can be treated with a stringent course of 
antibiotics, but there are a high number of cases of multi-drug resistant tuberculosis due 
to limited availability of drugs to complete a full course of treatment or poor compliance 
with the treatment protocol. This is especially true in cases in which patients also have 
another immuno-compromising infection such as HIV. [19-21] Therefore, a new 
approach to antibiotics for M. tuberculosis would be beneficial for these cases. 
Complement system proteins can be directly antimicrobial through the formation of the 
terminal complement complex (TCC) and have an additional function in the recruitment 
of other innate and adaptive immune factors and cells through the chemotactic and pro-
inflammatory properties of their degradation products (C3a, C5a, etc.). The TCC 
cytotoxic action occurs through the formation of a nanoscale transmembrane channel 
leading to loss of integrity of the pathogen bilayer membrane and osmotic lysis. [22, 23] 
Finally, there is currently only one FDA approved vaccine, Bacillus Calmette-Guerin 
(BCG), which has an efficacy rate of 0-80%.  If we can better understand and control 
macrophage response to the vaccine through novel adjuvants, we may be able to better 
improve the vaccine response and develop a improved way to treat the infection.  
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1.2 Specific Aims 
 The ability to control the body’s immune response has long been an important 
goal in biomaterials research. [2, 24-27] Macrophages represent an important target for 
immunomodulation as they are capable of a broad range of phenotypes that have been 
shown to be activated upon exposure to external stimuli. [17, 28, 29] Specifically, 
macrophage phenotype can be altered and phagocytosis mediated through the binding of 
Fc surface receptors to the Fc domains of bound antibody to antigen-antibody immune 
complexes. [28-32] By functionalizing microparticles with variable densities and 
amounts of Fc to simulate these immune complexes, downstream effects on macrophage 
phenotype or phagocytosis efficiency can be modulated. [31] Fc coated microparticles 
can also be used to activate the complement system which can lead to a wide variety of 
applications including antibiotics, vaccine development, and viral clearance. [10-13, 33] 
Microparticles offer an ideal platform for immunoengineering as they enable us to alter a 
variety of physical and biochemical characteristics to tune a desired response. [26, 30, 34-
37] While Fc receptor crosslinking in macrophages and complement system activation 
has been previously studied, it was not yet understood how Fc display on particles, and 
the combinatorial effects of Fc density and particle size, can affect these two systems. 
Therefore, this work focused on decoupling the effects of Fc density and microparticle 
size on macrophage phagocytosis and phenotype and on controlled complement system 
activation. Altering macrophage phenotype through Fc-mediated phagocytosis and 
activating the complement system can also have an impact on key adaptive immune 
components. This is why we applied Fc coated particle platform to better understand the 
tuberculosis vaccine, BCG.   
 The overall objective of this dissertation is to evaluate the effect of Fc particles 
on the humoral immune response. The overall hypothesis is that microparticles 
functionalized with a varied Fc density would provide a tunable platform for altering 
macrophage phenotype and humoral immunological effects.  
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1.2.1 Specific Aim 1: Characterize the effects of Fc functionalized microparticles 
on phagocytosis and macrophage phenotype.   
 The hypothesis is that a particle size and Fc density will affect macrophage 
response in a tunable manner. Functionalized microparticles with variable Fc densities 
were created. These particles were then delivered to macrophages and the amount of 
particle internalization was determined through flow cytometric and fluorescent 
microscopic analyses. Macrophage phenotype was characterized by evaluating gene 
expression of several cytokines using qRT-PCR. Cytokine secretion was then confirmed 
by testing for TNFα and IL-12 concentrations in conditioned media through ELISA.  
1.2.2 Specific Aim 2: Modulate complement system activation for directed 
bacterial cytotoxicity.   
  
 The hypothesis is a high Fc density coating will lead to high levels of complement 
system activation and result in high levels of bacterial cytotoxicity. Microparticles of 
various sizes and Fc coating densities were delivered to human serum aliquots to 
determine complement system activation. After complement stimulation, microparticles 
were collected and incubated with primary antibodies specific for various complement 
components to characterize the specific complement pathways involved. Deposition of 
complement components on particles was confirmed using flow cytometry. A Monte 
Carlo simulation was used to validate a model that showed variations in Fc density could 
result in nonlinear activation of the complement system, which was observed 
experimentally. The experiment was repeated in C1 and Factor B deficient sera to 
determine which complement pathways were activated. Our Fc coated particles were 
observed to be cytotoxic by incubation with bacteria and analysis with a live/dead 
fluorescent staining by flow cytometry. 
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1.2.3 Specific Aim 3: Evaluate the in vitro effects of Fc functionalized 
microparticles on BCG-macrophage interaction.   
 The hypothesis is that Fc primed macrophages will lead to increased BCG 
phagocytosis and lysosome maturation. The interactions of macrophages treated with 
BCG and microparticles compared to BCG alone were quantified using flow cytometry 
and fluorescent and confocal microscopy. The amount of nitric oxide produced by 
macrophages was quantified as a result of BCG and/or Fc coated microparticles.  
1.3 Innovation and Significance 
 The importance of innate immune components such as macrophages and the 
complement system is only paralleled by the complexity behind the intricate feedback 
systems controlling their activation. This fact makes these mechanisms both important 
foci of numerous research studies as well as difficult subjects of study. While the FcR 
and its corresponding activation pathways have previously been studied, applying this 
knowledge still holds great potential in the fields of biomaterials and vaccine 
development. Functionalizing microparticles with varied densities of Fc ligand provides a 
tunable method for modulating biophysical processes of macrophage phagocytosis, 
macrophage gene expression and phenotype, as well as complement system activation.  
This also represents the first time, to our knowledge, that the complement system has 
purposefully been activated through the use of a protein-functionalized biomaterial and 
applied as an antibiotic. These studies have identified Fc microparticles as a possible 
platform for a variety of clinical applications and could therefore aid in the translatability 
of this study. As M. tuberculosis primarily infects macrophages, the ability to deliver 
particles to macrophages and better engage macrophages with the BCG vaccine could 
greatly improve the efficacy of the vaccine and also offer a secondary option for infection 
treatment. This body of work is innovative through its application of a platform 
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technology to the problem of a rationally designed, initiated, and propagated “tunable” 





CHAPTER 2  LITERATURE REVIEW 
2.1 Macrophage Response 
 Macrophages are a key component of the immune system and perform a range of 
functions that span the innate and adaptive immune response. [17, 29, 38, 39] These cells 
reside in many different tissue spaces including the brain, lung, and lymphoid tissues. 
[40, 41] Recent studies have shown that some populations of tissue resident 
macrophages, such as microglia within the brain and Langerhans cells within the skin, are 
generated during prenatal development in the yolk sac. [29, 42, 43] For most 
macrophages, however, monocytes derived from myeloid progenitor cells generated 
within the bone marrow circulate through the body before entering the tissues as 
macrophages. [29] Macrophages respond to their surroundings due to stimuli to their 
numerous surface receptors. These surface receptors recognize a broad variety of inputs 
such as cytokines from nearby cells, pathogen associated molecular patterns displayed by 
pathogens, and apoptotic cells. Inputs from cytokines and crosslinking of surface 
receptors leads to phagocytosis and internalization of the original input (ie receptor or 
particulate) and further downstream internal signaling. [38, 39] While this role is the 
reason macrophages are typically thought of as first responders of the innate immune 
response, macrophages also play a key role in the adaptive immune system. Macrophages 
are capable of processing and presenting phagocytosed antigens to T and B cells as well 
as secreting cytokines that encourage recruitment of other immune cells.  [38, 44, 45] 
Despite the protective effect macrophages can have, these cells also play a role in the 
promotion of many disease states, including atherosclerosis [46, 47], tumor 
microenvironments [3, 48], and tuberculosis [19, 49-51].  
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2.1.1 Macrophage Phenotype 
 Traditionally macrophages were thought to have only two distinct 
phenotypes: inflammatory (M1) and anti-inflammatory (M2). Macrophage phenotype has 
since become a more complex field of study, due to the large variety of phenotypes that 
have been described and the resulting impacts of those different phenotypes on wound 
healing and tissue regeneration. [15, 17, 27-29] Recent reviews have defined four distinct 
phenotypes with many more possible. These distinct phenotypes are categorized by 
cytokine output as well as up-regulation of specific surface receptors as highlighted in the 
table below (Table 1).   
Table 1: Classification of Macrophage Phenotype.Summary of the various factors 
that can affect macrophage phenotype and the surface markers used to classify to 
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 Factors that can directly affect macrophage differentiation include the types of 
particulates and pathogens that are phagocytosed, as well as signaling cytokines released 
by initial responders. [15, 17, 27-29, 52] While previous studies have shown that 
stimulating macrophages in vitro with IL-4 and IL-13 results in alternatively activated 
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macrophages [16, 52], one group of researchers showed that the outcome can be 
confounded depending on the presence and timing of a “danger” signal such as LPS. 
When macrophages were pretreated with IL-4 and then stimulated with LPS, there was a 
significant increase in TNFα and IL-12, indicating a skew towards a pro-inflammatory 
response. However, when macrophages were treated with LPS and IL-4 simultaneously, 
there was a sharp decrease in TNFα and IL-12 production.[40, 53] These results highlight 
the sensitivity of macrophages to the multiple stimuli that could be encountered in vivo.  
2.1.2 Role of Fc Receptors 
 The Fc gamma receptor (FcγR) on macrophages recognizes the crystallizable 
fragment of IgG antibody molecules [39]. There are also additional Fc receptors on 
macrophages capable of recognizing other classes of antibodies. Antibodies are produced 
by B cells in response to encounters with presented antigen. B cells will originally 
produce IgM and IgD before antigen presentation which will lead to class switching. As a 
result of this, the B cells will now produce IgG, IgA, or IgE. [8, 9] Fc binding by 
macrophages initiates a number of signaling pathways [54] that lead to actin-myosin 
driven phagocytosis [55, 56]. FcR-mediated phagocytosis of opsonized particles proceeds 
through both biomolecular and biophysical pathways that result in engulfment of the 
opsonized particle within a phagosome. The ligation of Fc receptors has also been shown 
to decrease production of IL-12 and increase the production of IL-10 [57]. Ligation of 
FcRs has also been shown to drive T-cells into a Type 2 Helper T cell (TH2) phenotype 
[58], which leads to clonal expansion of B-cells and affinity maturation of produced 
antibody [59] and clearance of extracellular bacteria and parasites [60]. The Fc portions 
of immune complexes are also known activators for various components of the 
complement system, which then also aid in the recruitment of macrophages [61].  
Another study on the effects of FcRs in relation to Mycobacterium bovis and Leogionella 
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pneumophilia suggested that engaging the FcγR triggers downstream cell signaling that 
results in increased levels of lysosome maturation. [62]  
2.2 Complement System 
 The complement system represents another key, yet sometimes overlooked, 
component of the innate immune response. The complement system comprises a group of 
proteins that can become activated through one of three pathways: the classical, 
alternative, or lectin pathways (Figure 1). [22, 23, 63, 64] Both the classical and lectin 
pathways use C4 and C2 components, but recognize different binding sites. The classical 
pathway is typically activated through binding and formation of C1 proteins on the Fc 
regions of IgM or IgG molecules that have deposited on a cell or material surface. The 
lectin pathway was only recently discovered in 1990 and was found to activate through 
pattern recognition of mannose lectin regions on foreign pathogens.  Finally, the 
alternative pathway becomes activated when the C3 component undergoes hydrolysis and 
cleaves into its active components, which periodically binds and unbinds to surfaces, and 
does not receive an inhibitory signal. Once one of these pathways is triggered, the 
complement proteins are catalytically activated in a cascade-type manner. The result of 
this activated cascade is the deposition of proteins (C5b-9) on the surface of the pathogen 
and the formation of the membrane attack complex, also known as a terminal 
complement complex (TCC), on the surface of the pathogen. The TCC forms a 
transmembrane channel resulting in the lysis of the pathogen. [22, 23]  
 These deposited complement component proteins also interact with other immune 
cells such as macrophages to aid in the clearance of the targeted pathogen. [23, 33, 63, 
64] Recent studies have also shown that complement activation also plays a key role in 
the body’s response to tumors [23, 65, 66] and improves the effectiveness of vaccines by 
acting as an adjuvant [12, 13].  
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Figure 1: Overview of complement system activation pathways. The schematic 
illustrates the three different pathways of complement system activation which 
penultimately results in the formation of the terminal complement complex and 
subsequent cell lysis.  
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2.3 Microparticles for Immunomodulation 
 Biomaterials is an ever expanding field of applying biology and engineering 
design to create novel solutions to tissue regeneration, wound healing, drug delivery, 
imaging, and a wide variety of other biomedical goals. [41, 45] Particle based platforms 
can utilize multiple physical and chemical properties to generate a desired response. [26, 
30, 37, 67, 68] Applications utilizing immunomodulation include both activating the 
immune response, for example in the case of adjuvants, or suppressing the activation of 
immune cells, for example to combat autoimmune disease. [69, 70] Microparticles have 
successfully been coated with antibodies that bind to cell specific receptors, such as anti-
DEC-205 for dendritic cells [71] and anti-CD3 for T-cells [72], in order to increase cell 
activation and particle uptake.  The size of the particle has also been shown to be a key 
factor in a variety of immune processes such as phagocytosis [26, 30, 73, 74] and 
lymphatic uptake [13].  
 Current biomaterials related research has focused on evaluating macrophage 
phenotype in response to biomaterial implantation with the goal of reducing the 
inflammatory state [2, 27, 75]. Previous studies have shown that administering particles, 
specifically poly(D,L-lactic-co-glycolic acid) (PLGA) particles, can enhance maturation 
of dendritic cells. [76] This would suggest that particles can be used to drive a specific 
cell phenotype. One recent study demonstrated plating macrophages onto different 
micropatterned surfaces could alter the macrophage phenotype, indicating that purely 
physical factors such as particle size may affect macrophage differentiation. [77] The 
driving factors affecting macrophage phenotype only highlight the complicated feedback 
system controlling cell signaling and the opportunities for a platform that can induce a 
specific phenotypic response. 
 A study on the effect of liposome surface charge showed that positively and 
negatively charge surfaces activated the classical and alternative pathway, respectively 
while neutral liposomes did not activate any of the complement pathways. [78] Others 
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have shown that different particle materials are capable of activating the complement 
system in various degrees. [13, 79, 80] One group specifically showed that 
polyhdroxylanted nanoparticles were able to successfully activate the complement system 
by binding to the C3b component. However polymethoxylated nanoparticles were not 
successful in complement system activation. The resulting complement system activation 
also increased vaccine efficacy by having an adjuvant effect. [13] The complement 
system also becomes activated by bulk surfaces. In one study, bulk polystyrene was used 
as model biomaterial and the ensuing complement system activation was determined to 
derive from the interaction of proteins that had adsorbed from plasma. [81] 
2.4 Bacillus Calmette Guerin 
Mycobacterium tuberculosis, the agent that causes tuberculosis (TB), is the most 
devastating bacterial pathogen of humans. It is responsible for nearly 1.5 million deaths 
and 8 million new infections each year worldwide. Currently, there is one approved 
vaccine for human use against tuberculosis: the Bacillus Calmette-Guerin (BCG) vaccine, 
an attenuated strain of Mycobacterium bovis. While this vaccine is effective when 
administered to infants, the efficacy of the vaccine is greatly diminished in adulthood. In 
fact, reports on the efficacy of the vaccine vary from 0-80%. [19-21, 49] This wide range 
in efficacy highlights a need for vaccine and/or adjuvant alternatives; several have been 
tried including modified BCG, modified M. tuberculosis, subunit vaccines, naked DNA 
and viral-vectored vaccines, and double stranded RNA capsids. [21] BCG itself is an 
attenuated strain of M. bovis. [49, 82] The body of work studying this issue indicates that 
the lack of immunological response is due to the ability of M. tuberculosis to reduce the 
amount of MHC II presentation on antigen presenting cells, such as macrophages, and 
that adjuvants that non-specifically activate APC’s or promote cross priming of immune 
cells through both MHC I and II presentation may lead to a more effective immune 
response. [21, 83] Additionally, the BCG strain may have lost too much antigenicity due 
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to a high passage history, so some have focused on increasing the presentation of 
antigen.[49] In support of this hypothesis, one study showed that tissue resident 
macrophages and dendritic cells did not interact strongly with BCG after intradermal 
vaccination [82].  Therefore, increasing the interaction between these resident immune 
cells and the vaccine would likely improve vaccine efficacy.  
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CHAPTER 3  FC OPSONIZED MICROPARTICLES AFFECT 




 Uptake of particulate debris, fluid, and foreign substances by macrophages is a 
key aspect of the innate immune system [38, 39]. Macrophages are important generalist, 
first responder cells in the body that serve both recognition and degradative functions.  
Through recognition, engulfment, and processing of either self or non-self substances, 
macrophages remove waste; initiate, coordinate, regulate, and/or participate in immune 
responses; and monitor the body for deviations from homeostasis [84].   
 Biomedical applications that directly utilize phagocytosis stand to be substantially 
improved through greater understanding of the internalization process [85-87]. Particle 
internalization can be initiated through multiple pathways including toll-like receptors, 
scavenger receptors, complement receptors, chemokine or interleukin receptors, and the 
Fc receptor (FcR), which recognizes the crystallizable fragment of IgG antibody 
molecules [39]. Fc binding by macrophages initiates a number of signaling functions [54] 
that lead to actin-myosin driven phagocytosis [55, 56]. FcR-mediated phagocytosis of 
opsonized particles proceeds through both biomolecular and biophysical pathways that 
result in engulfment of the opsonized particle within a phagosome. After lysosome fusion 
to form a phagolysosome, oxidative, proteolytic, acidic, and other degradative processes 
decompose the engulfed substance [38, 39, 56]. The role of macrophages within the total 
immune response is broad, involving recruitment of many different cell types and 




 Adapted and Modified from Pacheco, Patricia, David White, and Todd Sulchek. "Effects of microparticle 
size and Fc density on macrophage phagocytosis." PloS one 8.4 (2013): e60989. 
 16 
interaction with cellular and molecular components to resolve the perceived “danger 
signal” [88]. For example, the Fc portions of immune complexes are also known 
activators for various components of the complement system, which then positively 
feeds-back to aid in the recruitment of additional macrophages [61]. Macrophages also 
assist in the progression from innate to adaptive immune responses. The ligation of Fc 
receptors decreases production of IL-12 [57], a cytokine key for the development of Type 
1 helper T cell (Th1) phenotype [58, 89] while also driving T-cells into the Type 2 helper 
T cell (Th2) phenotype [58].  Th2 cell development subsequently leads to clonal 
expansion of B-cells and affinity maturation of produced antibody [59], aiding in the 
clearance of extracellular bacteria, viruses, and parasites [60].   
 Macrophages perform two important tasks through phagocytosis: sequestration 
and degradation of self particles (e.g. dead cells and debris), and elimination of foreign, 
non-self matter. In principle, both tasks proceed through a combination of physical cues, 
such as particle size, shape, and deformability [68], as well as biological cues such as 
recognition of pathogen-associated molecular patterns (PAMPs) or opsonized particles 
[39]. Therefore, it is likely that both physical and biological mechanisms are significant 
to regulating phagocytosis in macrophages. Understanding the biophysical and biological 
cues which trigger macrophage phagocytosis is important to improved utilization of 
phagocytosis in therapeutic microparticle delivery to macrophages.  
 Micro- and nanoparticles are commonly used and studied in the field of 
biomaterials, and specifically the study of phagocytosis, for applications such as drug 
delivery, vaccine delivery and development, and cancer therapies [67, 69, 90, 91]. 
Microparticles have long been used to study phagocytosis [30, 68, 92-94] in part due to 
their chemical and physical uniformity as well as their application in clinical settings. 
Multiple modeling studies on phagocytosis of particles, including computational models 
of 4-100 nm particles [95-97] and 3-11 μm particles [74, 98-100], which include 
consideration of the effects of cell cytoskeleton and ligand density on phagocytosis. 
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Experimental validation of these approaches which combine the effect of particle size and 
receptor density has been more limited. Previous experimental studies of Fc-mediated 
phagocytosis using microparticles [56, 93] did not examine the importance of the density 
of Fc ligands in conjunction with the size of the particle. Increasing the density of Fc on 
opsonized sheep erythrocytes caused macrophages to increase production of IL-10 and 
decrease production of IL-12 [32]. However in this study the effect of size and shape of 
the erythrocyte on phagocytosis was not explicitly examined or decoupled from Fc 
density. Other studies have shown that the shape of the particle can have a strong effect 
on phagocytosis [68]. In another study, the Fc density was varied on a spherical particle 
to understand the effects on cell signaling and commitment of the macrophage to 
phagocytosis. This study utilized 5.6 μm polystyrene particles with two different Fc 
densities and found that a high Fc density led to complete closure of the phagosome 
around the microparticle while a low Fc density resulted in binding of the particle to the 
macrophage but not internalization [93]. Numerous studies on phagocytosis have shown 
that particle size greatly affects the average number of microparticles internalized by the 
macrophage [30, 68, 90], but these did not address the impact of Fc density on 
internalization. Modeling and experimental approaches found that smaller particles are 
uptaken through both passive and active zipper mechanisms [74]. This study also found 
that actin polymerization is important for more regular phagocytic cups as it stabilizes 
receptor-ligand binding and suggests that active phagocytosis enables faster engulfment 
of the particle.  
 To evaluate the hypothesis that both Fc density and particle size significantly 
impact internalization by macrophages and macrophage phenotype, we investigated the 
effects of Fc ligand surface density on phagocytosis for a variety of particle sizes. As 
macrophages may utilize different physical and biochemical mechanisms for clearing 
foreign objects of a wide range of sizes (submicron to greater than 5 μm), we explicitly 
decoupled the effects of the physical signal resulting from particle size and the biological 
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signal resulting from variation in Fc density. By decoupling the biological and physical 
signals, we can better optimize particle-mediated delivery of therapeutic payloads to 
macrophages. 
3.2 Materials and Methods 
3.2.1 Microparticle Opsonization 
 Carboxylated yellow-green fluorescent polystyrene microparticles were purchased 
from Polysciences. To examine the effects of a broad range of sizes on internalization 
efficiency, we used 0.5 μm, 1 μm, 2 μm, 3 μm, and 4.5 μm particles. A schematic 
showing the Fc opsonization process is shown in Figure 1. For phenotype studies, 
nonfluorescent polystyrene microparticles, 0.5 μm and 1 μm, were purchased from Bangs 
Laboratories. The microparticles were incubated in a 1-2 mg/mL bovine serum albumin 
(BSA) (Sigma Aldrich) solution to adsorb a layer of antigen onto the particle surface. The 
concentration of BSA was chosen to be 10 times the saturating concentration for the 
amount of beads, as determined from manufacturer’s specifications using the equation 
below (Equation 1). 
 
S = ( 6 / ρ D) (C)  Equation 1 
 
 Where S is the amount of protein required to saturate the particle surface, ρ is the 
density of the particle, D is the diameter of the particle, and C is the capacity of the 
particle for a specific protein. For BSA, the value of C was set as 3 mg/m
2
 in accordance 
with the manufacturer’s specifications.
 
The concentration of BSA was increased in direct 
proportion to the total microparticle surface area to remove the density of the antigen as 
an experimental variable. To create particles with different densities of exposed Fc 
domains (i.e. different valencies), sheep (Abcam) or rabbit (Life Technologies) 
polyclonal anti-BSA IgG antibody was added in decreasing antibody mass to BSA mass 
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ratios thereby producing a range of exposed Fc densities, or Fc density ratio. We 
identified a 1:1 ratio of added antibody to antigen that represents a condition of maximum 
Fc coverage. Dilutions of 1:2, 1:5, 1:10, and 1:50 ratio of added antibody to antigen were 
tested. For later experiments a molar ratio was followed with 2 moles of antibody to 1 
mole of BSA, or a 2:1 ratio, identified as correlated to a maximum Fc coverage. The 2:1 
molar ratio was found to be within 10% of added antibody of the 1:1 weight ratio. No 
added IgG, or a 0:1 ratio, indicates microparticles coated only with BSA antigen. A table 
of the amount of BSA antigen and opsonizing antibody added to each particle size is 
shown in Supplemental Figure 2. Microparticles were incubated with protein at room 
temperature for at least 2 hours in phosphate buffered saline (PBS) at a pH ~7.2 for all 
protein-binding steps. After each binding step, the microparticles were washed three 
times by centrifugation and PBS exchange. We observed only slight particle clustering in 
the case of 0.5 μm particles and negligible clustering for particles of other sizes. To verify 
the availability of Fc domains and to quantify the amount of Fc presented on each 
microparticle, a 10 μL aliquot from each Fc density condition was incubated with a 
TexasRed fluorescently labeled rabbit anti-sheep IgG secondary antibody or DyLight 650 
labeled donkey anti-rabbit (Abcam). This process was repeated to create duplicate or 
triplicate particle groups.  
3.2.2 Cell Culture 
 RAW 264.7 murine macrophages were used in the internalization assay. These 
cells were a gift from the lab of Niren Murthy and were originally purchased from ATCC 
(Manassas, VA). The cells were cultured in complete media composed of DMEM (Sigma 
Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS) (Atlanta 
Biologicals, Atlanta, GA) and 0.1% penicillin/streptomycin (P/S), and were grown in a 
humidified incubator at 37°C with 5% CO2. For the internalization assay, cells were 




per well. The cells were incubated in complete media for 24-48 hours until fully adherent. 
Supernatants were aspirated and the plates were washed twice with PBS. After the final 
aspiration, 0.5 mL of fresh DMEM followed by the microparticles, were added to each 
well.  
 L929 murine fibroblast cells were cultured as a source for M-CSF for bone 
marrow derived macrophage differentiation. These cells were purchased from ATCC and 
then grown in DMEM supplemented with 10%FBS and 1% P/S within a humidified 
incubator at 37°C and 5% CO2. The cells were initially plated at 470,000 cells were 
plated per 75cm
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tissue culture treated flask. After one week, the cells were replated and 
the conditioned media was collected and passed through a 0.8 μm filter.  The L929 
conditioned media was then aliquoted and stored at -20°C.  
 Bone marrow derived macrophages were generated using previously published 
methods. [101, 102] The femurs and tibias from 5-8 week old female C57Bl/6 mice 
(IACUC A13005) were isolated and cleaned. The ends of each bone were clipped to 
expose the marrow. The basal media of DMEM/F-12 was used to fill a 10 mL syringe 
and was then passed through a 25G needle inserted into the bone marrow. This allowed 
us to flush out the bone marrow into a sterile petri dish. The bone marrow solution was 
then passed through an 18G needle multiple times to break up any clumps. We then 
transferred the solution through a 70 μm cell strainer into a 50 mL conical tube. The cell 
solution was then pelleted through centrifugation at 300G for 10 minutes. Following 
media decantation, the cells were resuspended in red blood cell lysis buffer at 
approximately 2.5 mL per animal. The cell solution was centrifuged at 300G for 5 
minutes and then washed with DMEM/F-12 twice. After the final wash, the 
differentiation media was then added and cell concentration determined using a 
hemocytometer. The differentiation media was composed of DMEM/F-12, 10% FBS, 1% 
penicillin/streptomycin, and then supplemented with 20% L929 conditioned media. The 
collected bone marrow cells were plated in 10 cm non-tissue culture treated plastic petri 
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dishes at a concentration of 500,000 cells/mL in 10 mL. Cells were grown in a 
humidified incubator at 37°C and 5% CO2. On day 3, 5 mL of fresh differentiation media 
was added. On day 7, the dishes were washed with PBS to remove non-adherent cells, 
and fresh differentiation media was added. The cells were then removed by gently 
scraping as cell detachment solutions that were either enzymatic, such as trypsin and 
trypsin-EDTA solutions, or non-enzymatic, such as CellStripper (Corning), were found to 
be ineffectual and detrimental to cell health. The cells from all dishes were then collected 
in 50 mL conical tubes and centrifuged at 300 G for 10 minutes. The media was decanted 
and fresh differentiation media was added again. Cells were counted using a 
hemocytometer and the volume was adjusted to a concentration of 5E6 cells/mL. 
Approximately 1E6 cells were plated per well on a 6-well plate in differentiation media 
and allowed to incubate overnight prior to experiment. Successful macrophage 
differentiation was determined by adding fluorescently labeled antibodies for 
macrophage specific cell surface markers, including PE labeled F4/80 and PerCP-Cy 5.5 
labeled CDllb antibodies. Macrophages were first incubated with anti-CD16/32 to block 
Fc receptors and a PerCP-Cy 5.5 anti-rat IgG2b K was used as an isotype control. This 
staining procedure showed that our differentiation technique yielded an over 80% 
macrophage purity sample.  
3.2.3 Internalization Assay 
 Approximately 20-25 microparticles per cell were added to each well of plated 
macrophage cells for each condition tested. The cells and microparticles were gently 
mixed and then allowed to interact in a humidified incubator at 37°C with 5% CO2 for 
approximately 1 ½ hours. A duplicate set of plated samples were incubated at 4°C to 
determine the rate of microparticle adhesion. After the incubation period, the well 
contents were aspirated and washed with PBS twice to remove particles that did not 
interact with the adherent cells. 1 mL of PBS was added after the final washing was 
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complete. The well was then scraped using a standard cell scraper and the entire contents 
were transferred to a microcentrifuge tube for analysis using flow cytometry. The 
internalization assay is illustrated in Figure S1 and was repeated 4 times for each Fc 
density and size condition.  
3.2.4 Flow Cytometry   
 All samples were analyzed using a flow cytometer (Accuri C6) immediately after 
microparticle-cell incubation, collection, and mixing. To measure the amount of 
TexasRed-labeled secondary antibody per microparticle, the 630 ± 30 nm bandpass filter 
(suitable to detect TexasRed) was used in conjunction with the 533 ± 30 nm bandpass 
filter to detect the yellow-green fluorescence of the microparticle core. As the TexasRed 
emission spectrum overlaps part of the yellow-green fluorescence of the particles, results 
were compensated by subtracting the overlapping signal of the secondary antibody from 
that of the particle using the compensation tool in the CFlowPlus software (BD, Franklin 
Lakes, NJ). Due to high levels of overlapping fluorescence from the particle and 
secondary antibody, non-fluorescent microparticles and a FITC-labeled secondary 
antibody were used to estimate the density of exposed Fc on non-fluorescent particles. 
Flow cytometry was also used to estimate the particle concentration for each condition. 
To determine the number of microparticles phagocytosed for each Fc density condition 
and particle size, the populations were analyzed using forward scatter and microparticle 
core fluorescence. Events were gated on forward scatter to separate the larger cells from 
the smaller microparticles. Three populations were delineated: macrophage cells alone, 
microparticles alone, and microparticles collocated with cells. The number of 
microparticles per cell was then determined by measuring the mean fluorescent intensity 
(MFI) of the dual-signal population and dividing it by the average MFI of one particle 
within the dually-positive population, in accordance with previous methods [103]. 
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ANOVA followed by Tukey-Kramer HSD post analysis was performed to determine 
significance using JMP software (SAS, Cary, NC).  
3.2.5 Microscopy 
 In preparation for fluorescence microscopy and confocal microscopy, cells were 
plated onto sterile coverslips within a 6-well plate before the internalization assay. Each 
well was then washed with PBS 3 times and 0.5 mL of PBS added to each well after the 
final washing. The cells were stained in a 5 μg/mL solution of a lipid specific cell 
membrane stain, FM4-64X (Invitrogen, Carlsbad, CA) for 1 minute. After the incubation 
period, the cells were fixed with a 4% paraformaldehyde solution for 10 minutes and then 
rinsed 3-5 times with PBS. The cells were then treated with 4',6-diamidino-2-
phenylindole (DAPI) to stain nuclear DNA. After a short incubation period, the 
coverslips were then removed from the well and transferred to a standard microscope 
slide. The stained cells were visualized with a Nikon Ti epi-fluorescence microscope and 
Zeiss LSM 510 VIS confocal microscope. Images were processed with the Nikon 
Elements and Zen Lite 2011 software.  
3.2.6 Macrophage Phenotype Conditions and Cytokine Production 
 Approximately 20 microparticles per cell were added to each well of plated bone 
marrow derived macrophage cells for each condition tested. The 0.5 μm and 1 μm 
particles sizes and 2:1, 1:1, 1:5, and 0:1 (BSA only) antibody to antigen molar ratio were 
tested to determine their effect on macrophage cytokine production and predict 
macrophage phenotype. LPS (Sigma), at a final concentration of 1μg/mL, was used as a 
positive control for a M1, classically activated macrophage, and IL-4 (Antigenix), at a 
final concentration of 10ng/mL, was used a control for a M2, alternatively activated 
macrophage.  The bone marrow derived macrophages and microparticles or chemical 
stimulus were gently mixed and then allowed to interact in a humidified incubator at 
37°C with 5% CO2 for approximately 4 hours. To determine if Fc coated particles are 
 24 
capable of shifting the response of classically or alternatively activate macrophages, after 
an initial 4 hour incubation with LPS or IL-4, 0.5 μm and 1 μm particles with a 2:1 
antibody to antigen Fc coating were added for an additional 4 hours. These phenotype 
incubation studies were repeated 3 times with duplicate wells for each condition. After 
the incubation period, the media from each well was collected and centrifuged at 1500 
RPM for 10 minutes. The supernatant was then collected and frozen at -80°C for future 
cytokine secretion analysis. The wells were then washed with PBS twice to remove 
particles that did not interact with the adherent cells. Cell lysis buffer was added after the 
final washing and RNA collected using the RNeasy kit (Qiagen) in accordance with 
manufacturer’s instructions. RNA purity and concentration was determined using a 
NanoDrop by measuring absorbance at 230 nm, 260 nm, and 280 nm. cDNA was then 
synthesized using the iScript Advanced cDNA Synthesis Kit for RT-qPCR (BioRad) to 
produce 500ng of cDNA for each condition. Qualitative real-time polymerase chain 
reaction was carried out using the Fluidigm 96.96 Gene Expression Profiling Chip using 
primers purchased through Fluidigm. The complete list of primers tested is listed in Table 
2 and all primers were tested in triplicate on the chip. The threshold cycle (CT) values 
were provided for each condition and cytokine or receptor as a result of the Fluidigm 
96.96 Gene Expression Chip analysis. All values with a “Pass” rating were used to 
calculate the average CT values for each condition and cytokine or receptor. These values 
were then used to calculate the fold change in mRNA expression for each cytokine or 
receptor and uploaded into the RT
2 
Profiler PCR Array Data Analysis online tool 
(Qiagen) to calculate significance and cluster plots. To confirm that mRNA expression 
level corresponds to secreted protein amount, an ELISA (eBiosciences) was performed, 
according to manufacturer’s instructions, to test for the following cytokines: TNFα, IL-







Table 2: Primers used for qRT-PCR Analysis 
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3.3.1 Fc Density Increases with Antibody to Antigen Ratio 
 The Fc density was estimated for each surface dilution and particle size using the 
MFI of the secondary antibody signal that was normalized to the maximum saturated 
value. The normalized MFI decreased as the Fc was diluted both for the larger particles 
(4 μm) and smaller particles (1 μm). (Figure 2 and Figure 3: Normalized mean 
fluorescent intensity to surface area and maximum Fc density.) These data indicate that 
Fc density was successfully manipulated for each particle size. Similar trends in Fc 
density were observed by flow cytometry for the fluorescent particles of all sizes used in 
the internalization assays (Figure A 1, A 2).  
 
Figure 2: Normalized mean fluorescence intensity of microparticles labeled with 
fluorescently conjugated secondary antibodies.Decreasing normalized MFI 
corresponds to decreased Fc density for fluorescent particles. Due to possible non-
specific absorption of the secondary antibody and difficulty in fully compensating for the 
high background fluorescence of the microparticle core, nonfluorescent microparticles 












Figure 3: Normalized mean fluorescent intensity to surface area and maximum Fc 
density.  
Confirms that as the Fc density increases, the normalized MFI increases as well. The MFI 
for each Fc condition and particle size was first normalized by the particle surface area 
and then normalized to the value for the highest Fc density of 1:1.   
3.3.2 Effects of Fc Density on Microparticle Adhesion to Cell Surface 
 To determine the influence of Fc density and particle size on microparticle 
adhesion to macrophages, we performed the same internalization assay at 4°C, a 
temperature which inhibits internalization but not attachment [30, 94]. The average 
number of microparticles attached per cell was estimated from flow cytometric analysis 
for each Fc density and particle size condition (Figure 4). ANOVA was conducted to 
examine the independent effect of Fc density and particle size on cell attachment. 
Attachment of the 0.5 μm particles was significantly greater than that for the other four 
sizes. High Fc density also increased attachment of the 1 μm particles, but it did not 
enhance adhesion for the other particle sizes. Therefore, Fc does not play a strong role in 
particle attachment, with the exception of 1 μm particles at high density of Fc. However, 
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the lack of cellular activity at this temperature (active engulfment, receptor recruitment, 
etc.) may alter the adhesive properties at physiological conditions. 
 
Figure 4: Average number of attached microparticles for each particle size and Fc 
density condition. As particle size increases, so does the degree of attachment. Overall, 
Fc density was not a significant variable for opsonized and BSA-only particles. †- 
Significantly different (SD) from 1:1, ‡- SD from 1:2, with p < 0.05, (N=2) 
3.3.3 Effects of Fc Density on Microparticle Internalization 
 The average number of microparticles internalized per cell was measured with an 
internalization assay at 37 °C (Figure 5a). ANOVA of the average number of 
microparticles internalized per cell showed that both size and Fc density are significant 
variables at physiological temperatures. For smaller and medium-sized particles (0.5 μm, 
1 μm, and 2 μm), the number of microparticles internalized per cell was significantly 
greater for the higher Fc density conditions of 1:1 and 1:2 than the lower Fc density 
conditions of 1:10 and 1:50. There was a significant decrease in the average number of 
microparticles internalized per cell for the 3 μm and 4.5 μm particles. Fc density was not 
a significant factor in the internalization of larger 3 μm and 4.5 μm particles. In addition, 
larger particles (3 μm and 4.5 μm) were generally internalized at lower numbers than 
small and medium-sized particles (0.5 μm, 1 μm, and 2 μm), for a given Fc condition. 
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However it should be noted that the medium-sized 2 μm particles showed an increase in 







Figure 5: Average number of microparticles internalized per cell for each particle 
size and Fc density condition. 
(A) Average number of microparticles per cell for each particle size for the various Fc 
density conditions. (†- Significantly different (SD) from 1:1, ‡- SD from 1:2, ♦- SD from 
BSA Only, with p < 0.05). These values were also illustrated through fluorescent 
microscopy by comparing images taken of RAW264.7 macrophages incubated with Fc 
functionalized particles.   (B) Representative images for each size with the maximum Fc 
density ratio of 1:1. (C) Representative images for each size with the minimum Fc 
density ratio of 1:50. Scale bar represents 20 um. (N=4) 
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 Representative images of the macrophages and microparticles after incubation are 
shown for the high Fc density ratio of 1:1 and the low Fc density ratio of 1:50 (Figure 5b, 
c). Inspection of these images illustrate the extent to which internalized microparticles are 
not distributed equally among macrophages, but instead tend to be phagocytosed by a 
subset of cells, especially for smaller particles functionalized with a high Fc density.  
While the average number of phagocytosed microparticles per cell was significantly 
reduced for large particle sizes, the total volume of phagocytosed particles per cell 
increased with particle size. The total surface area of the internalized particles was also 
maximal for the 4.5 μm particles (Figure 6).  
 
Figure 6: Average total volume and surface area of internalized microparticles. 
Average calculated volume and surface area of microparticles internalized for the 
maximum Fc condition of 1:1 for each particle size. (N=4) 
3.3.4 Combined Effects of Fc Density and Microparticle Size on Phagocytic 
Activity of Macrophages 
 The previous data show the decoupled effects of particle size and Fc density on 
the number of internalized microparticles. Since the number of macrophages plated was 
constant for each tested condition, we were able to compare the percentage of total 
macrophages that were phagocytic for each treatment using flow cytometry data. We 
considered a macrophage to be phagocytic if it contained at least one microparticle. The 
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percentage of phagocytic macrophages was found to be strongly dependent on both the 
particle size and the particle Fc density (Figure 7a). Interaction with the smaller particles 
(0.5 μm and 1 μm) at a low Fc density resulted in a greater percentage of phagocytic 
macrophages than with high Fc density. In contrast, the larger particles (3 μm and 4.5 
μm) resulted in a slightly greater percentage of phagocytic macrophages for the high Fc 
density condition. For the 2 μm particle treated cells, the average percentage of 
phagocytic macrophages remained relatively constant regardless of Fc density, and was 
consistently higher compared to the other particle sizes.  
 Combining the results of macrophage phagocytic activity with the average 
number of particles internalized shows that for small particles (0.5 and 1 μm) a smaller 
percentage of the macrophages may be phagocytic, but they internalize a relatively large 
number of particles. The shift to a higher fluorescence signal for the high Fc density 
condition, observable for the 0.5 μm, 1 μm, and 2 μm particles, indicates that an 
increased average number of particles were internalized by phagocytic cells. In addition, 
there is an increase in the number of non-phagocytic cells seen in the 0.5 μm and 1 μm 
high Fc density histograms compared to the low Fc density, as indicated by an increased 
count of low fluorescence events. (Figure 7b) There was no observable shift in 
fluorescence dependent on Fc density for the larger particles of 3 μm and 4.5 μm. 
However this was expected as Fc density was a not a significant variable for the larger 
particles in our internalization studies. These data support the hypothesis that while the 
smallest particles (0.5 μm and 1 μm) functionalized with the highest Fc density are 
internalized in greater numbers, a smaller number of macrophages are involved in the 
internalization process.  
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Figure 7: Effects of Fc density and particle size on the macrophage population. 
(A) Percentage of phagocytic cells that each Fc density condition for each particle size 
with a dashed line to illustrate trends. (N=4) (B) Representative histograms of the FITC 
intensity for macrophages incubated with particles functionalized with the maximum Fc 
density of 1:1 and the minimum Fc density of 1:50. These histograms illustrate two 
groups: macrophages that have internalized at least one particle (phagocytic cells) and 
macrophages that did not internalize a particle (non-phagocytic cells).   
 
3.3.5 Fc density and Microparticle Size Affect Macrophage Cytokine Expression 
 The results of the mRNA expression analysis suggest that both Fc density and 
microparticle size do affect expression. The fold change was calculated using two 
reference genes, GAPDH and RPL13a, as the third reference gene, Actβ, failed across the 
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chip. While the levels of GAPDH and RPL13a did change across different conditions, the 
expression did not significantly change when the fold change values were calculated 
using a single reference gene. A cluster plot showing the overall gene expression shows 
how the magnitude of expression shifts across all tested conditions (Figure 8).  This 
shows the greatest changes occurring for the LPS and LPS + 1µm 2:1. The fold change 
graphs for each cytokine or receptor are grouped according to suggested functional 
phenotype: iNos, IL-12α, IL-12β, and Il-27β associated with M1 macrophages; IL-1α, IL-
1β, and IL-6 associated with M1 and M2b macrophages; IL-10, IL-1ra, TNFα, TGFβ, and 
Fcγr associated with M2a and M2c macrophages; and IL-18, IFNα, and IFNβ associated 
in some cases with M1 macrophages. [1, 28, 52] 
 
Figure 8: Cluster plot of magnitude of mRNA expression across all conditions 
 
 The cluster plot for 0.5 µm treated cells shows that the 2:1 and 1:1 functionalized 
particles elicited a similar response (Figure 9). It also suggests an inversion in gene 
expression from the untreated macrophage only group. ANOVA analysis showed the 
macrophages treated with 0.5 μm 1:1 Fc particles significantly different from the 
untreated macrophages, and macrophages treated with BSA only or 1:5 Fc particles. The 
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2;1 Fc condition was also significantly different from the BSA only coated condition. The 
fold change for each gene and condition compared to the untreated macrophage only 
group confirms this observation, but there is considerable variation across each condition. 
The high Fc density conditions of 2:1 and 1:1 resulted in increased expression of iNos, 
IL-12β, IL-1α, IL-1ra, and TNFα. Compared to the low Fc density 1:5 and BSA only 
conditions, the high Fc density treated groups resulted in lower expression levels of 
IFNα, IFNβ, and FcGr. We also see slight variations in IL-27β, IL-1β, IL-10, TGFβ, and 















Figure 9: Effects of 0.5 μm particles and Fc density on cytokine and receptor mRNA 
expression.  
(A) Cluster plot shows the shift in magnitude of gene expression and (B) Fold change 
graphs show expression levels compared to untreated macrophages. *, from Cells Only, 





The 1 µm particle cluster plot suggests that the 1:1 had the greatest impact on gene 
expression (Figure 10). ANOVA analysis showed the macrophages treated with 1 μm 1:1 
Fc particles significantly different from the untreated macrophages. The plot also shows 
that the highest Fc density condition of 2:1 resulted in minimal expression of most genes 
with the exception of TNFα. The fold change values show the same variability seen in the 
0.5 µm treated groups.  There are less difference between Fc density treatment and 
expression for a particular gene. The exception appears to be for iNos, IL-12β, and 
TNFα. Increasing the Fc density resulted in decreasing expression of IL-12α, IL-6, IL-10 
and Fcγr compared to macrophages treated with BSA coated particles. Overall, the 
addition of 1 μm particles resulted in the increased expression of IL-1α and IL-1ra 
compared to untreated macrophages.    
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Figure 10: Effects of 1μm particles and Fc density on cytokine and mRNA 
expression levels.  
(A) Cluster plot shows the shift in magnitude of gene expression and (B) Fold change 
graphs show expression levels compared to untreated macrophages. *, from Cells Only, 





 LPS was given to macrophages as a positive control to represent classically 
activated macrophages. The cluster plot for the LPS pretreated groups shows that adding 
high Fc density coated microparticles can invert the macrophage response, even though 
the LPS is still present (Figure 11). ANOVA analysis showed that the LPS only group 
and the LPS pretreated groups with 0.5 μm and 1 μm 2:1 Fc particles were significantly 
different from the untreated macrophages. The macrophages pretreated LPS and then 0.5 
μm 2:1 Fc particles were also significantly different from macrophages treated with LPS 
alone. Specifically, a decrease in IL-12α, IL-12β, IFNβ, IL-1α, IL-6, IL-10, and TNFα as 
seen compared to the LPS only treated conditions. The addition of 0.5 μm Fc particles 
results in a stronger decrease in expression compared to the addition of the 1 μm Fc 
particles. There was an increase in expression of iNos after the addition of Fc coated 
particles. The expression for IL-27β, IL-18, IFNα, and TGFβ remained relatively 
unchanged across the different LPS and LPS with Fc particles conditions.  
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Figure 11: Effects of the addition of high Fc density particles after LPS treatment on 
cytokine and receptor mRNA expression.  
(A) Cluster plot shows the shift in magnitude of gene expression and (B) Fold change 
graphs show expression levels compared to untreated macrophages. *, from Cells Only, 


















 The IL-4 treated macrophages acted as a representation of alternatively activated 
macrophages that are typically anti-inflammatory. The cluster plot for the IL-4 treated 
conditions shows a similar inversion when the high Fc coated particles were added 
(Figure 12). The plot also shows the IL-4 treated and untreated macrophages respond in a 
similar manner with the exception of IL-1α and IL-12α. The addition of 0.5 μm Fc 
particles results in minimal expression across a majority of the genes while adding 1 μm 
Fc particles leads to an increased expression of the previously minimally expressed 





Figure 12: Effects of the addition of high Fc density particles after IL-4 treatment 
on cytokine and mRNA expression levels. 
(A) Cluster plot shows the shift in magnitude of gene expression and (B) Fold change 






3.3.6 High Density Fc Particles Result in Significant Increase of TNFα and IL-12 
 To confirm the mRNA gene expression levels also resulted in secreted protein, an 
ELISA was performed on frozen aliquots of the conditioned media from experimental 
conditions. IL-10 and IL-1α were tested, but results were below the detection level of the 
assay. However successful results were obtained for TNFα and IL-12, with the exception 
of LPS treated groups which exceeded the limit of the assay. This was seen even after a 
1:100 dilution compared to the other treated groups. The amount of TNFα produced by 
macrophages treated with 0.5 μm with high Fc densities of 2:1 and 1:1 was significantly 
higher than the untreated macrophages as well as the BSA only coated and low Fc 
density particle condition of 1:5. In the 1 μm treated conditions, only the 1:1 Fc condition 
was significantly higher that the untreated condition.  
 
Figure 13: Amount of TNFα is affected by particle size and Fc density.  
TNFα is significantly increased for (A) high Fc densities coated 0.5 μm particles but (B) 
only for the 1:1 Fc density in 1 μm particle treated cells. (N>5, * denotes significance 
compared to the Cells Only condition with p<0.05) 
 
 For the IL-4 treated macrophages, the addition of high Fc density particles lead to 
a significant increase in TNFα production (Figure 14). The addition of 0.5 μm Fc 
particles to IL-4 treated macrophages resulted in similar levels of TNFα produced in non-
IL-4 treated macrophages. However, the addition of 1 μm particles to IL-4 treated 





                 
Figure 14: Amount of TNFα increases for IL-4 treated macrophages with the 
addition of high Fc density particles.  
Media from IL-4 only treated macrophages was collected after 4 hours while pretreated 
macrophages were treated with IL-4 for 4 hours and then particles were added for an 
additional 4 hours. N>5, * denotes significance compared to the IL-4 only condition with 
p<0.05 
 
 The amount of IL-12 secreted by 0.5 μm high Fc density particle treated 
macrophages was significantly higher than untreated cells (Figure 15A). However, there 
were not significant changes in IL-12 secretion for any of the 1 μm treated macrophages 
(Figure 15B). While there were no significant changes, the IL-12 production did increase 
for high Fc 1 μm treated macrophages. IL-12 production was significantly increased for 
in IL-4 treated macrophages when 0.5 μm and 1 μm high Fc density particles were added 





Figure 15: Amount of IL-12 is affected by particle size and Fc density. 
IL-12 is significantly increased for (A) high Fc densities coated 0.5 μm particles but (B) 
there was no significant difference in 1 μm particle treated cells. (N>4, * denotes 
significance compared to the Cells Only condition with p<0.05) 
 
 
                    
Figure 16: Amount of IL-12 increases for IL-4 treated macrophages with the 
addition of high Fc density particles. 
Media from IL-4 only treated macrophages was collected after 4 hours while pretreated 
macrophages were treated with IL-4 for 4 hours and then particles were added for an 
additional 4 hours, N>5, * denotes significance compared to the IL-4 only condition with 
p<0.05 
3.4 Discussion 
 One important mechanism for recognizing threats in the body is opsonization—
the coating of invading pathogens with antibodies marks them as a “threat” or a “danger 
signal”.  This process can prevent biological activity of pathogenic molecules through 
steric interference (e.g. interfering with binding to cells or other biological targets), but 
A) B) 
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also tags the pathogen for recognition by macrophages and other antigen-presenting cells 
through the external orientation of the constant region of the antibody molecule known as 
the crystallizable fragment (Fc) [104].  
 In these studies we quantified the phagocytic activity of macrophages as a 
function of Fc density and particle size. We successfully varied the Fc density on 
microparticles for all tested sizes. We then analyzed the effects of Fc density on 
attachment alone by conducting a low temperature study. We found that while particle 
size did play a role in attachment, Fc density did not. The results of our particle 
internalization assays showed a strong dependence between the Fc density and particle 
size on the average number of microparticles adhered to and internalized by the 
macrophage population (Figure 17). While size dependence of particles has been shown 
to affect phagocytosis in previous studies [30, 73, 105], this is the first study to look at 
the combined effects of Fc density and particle size on phagocytosis, which both play an 
important role [95]. Smaller particles (0.5 μm and 1 μm) showed a strong correlation 
between Fc density and the average number of internalized microparticles per cell. 
However for the larger particles (3 μm and 4.5 μm), an increase in Fc density resulted in 
no significant change in the average number of microparticles phagocytosed per cell. For 
the 2 μm BSA-only coated particles, an apparent anomaly from the general trend was 
seen in the average number of internalized particles per cell. The BSA-only particles 
were internalized in significantly higher levels compared to the Fc-functionalized 
particles. Others have shown that BSA-only particles can be internalized by 
macrophages, most likely through scavenger receptors [106, 107]. However, the 2 μm 
particle may represent a special case due to the topography of the macrophage membrane. 
Previous studies have shown that the macrophage membrane ruffles are spatially tuned 
with an average curvature of approximately 2 μm [30], suggesting a mechanism for 
physical selection of particles by size. 
 47 
 
Figure 17: Summary of the average number of attached and internalized 
microparticles per cell for each particle size and Fc density condition.   
(A) The attachment of particles to macrophages does not have a strong dependence on 
microparticles size and Fc density. (B) The internalization of particles by macrophages is 
highly dependent on microparticle size and Fc density with an overall trend of the 
average number of internalized particles decreasing as microparticle size increases and Fc 
density decreases. 
 
 The fluorescent microscopy images of the internalization of small particles (0.5 
μm and 1 μm) (Figure 5b, c) showed a great disparity in the phagocytic activity of 
individual macrophages, which we confirmed through further flow cytometry analysis 
(Figure 7).  High density of Fc resulted in an increase in phagocytosed particles, but also 
an increase in cells that do not phagocytose any particles (Figure 7b, 0.5 μm and 1 μm). 
Since our macrophage line is assumed to be relatively homogenous, the enhanced activity 
seen only when small particles were added, could be due to a positive feedback 
mechanism that causes cells that initially internalize particles to then more actively search 
for new particles.   
 One important goal of our study is to develop a set of design parameters by which 
we can better deliver particles to macrophages for specific biomedical applications. It 
may be useful to target the microparticles to a subset of macrophages by defining a set of 
physical and biochemical signals through a combination of particle size, avidity, and/or 
 48 
other (as yet untested) receptor ligands for “designer drug” therapies. We found the 
percentage of phagocytic cells is dependent on both particle size and Fc density. The 
maximum number of particles per cell were internalized for the smaller 0.5 μm and 1 μm 
particles functionalized with high Fc densities, despite only approximately 65% of the 
cells classified as phagocytic. The mid-sized particles of 2 μm are phagocytosed by the 
highest percentage of macrophages (90%), regardless of Fc density. The larger 3 μm and 
4.5 μm particles, while only phagocytosed by a smaller portion of the macrophage 
sample, nonetheless accounted for the greatest amount of total volume of microparticles 
phagocytosed.  
 Our attachment data shows that the initial interaction and attachment of the 
microparticle with the macrophage was most strongly affected by particle size. However, 
phagocytic activity and particle internalization was found to be dependent on both 
particle size and Fc density. The kinetics of internalization may also influence the 
phagocytic activity of macrophages. A previous study investigated the internalization 
rates of particles from 3-9 μm and found no significant difference in the phagocytic rate 
for the sizes tested, even when particles were functionalized with Fc. However, 
internalization rates of smaller particles and the effect of Fc density were not evaluated 
[30]. 
 A possible explanation for a significant dependence on size in the initial and 
ongoing processes of phagocytosis has been posited to result from the dynamics of cell 
signaling components recruited in the process. A theoretical model suggests that larger 
particles will require the cell membrane receptors to diffuse over larger distances 
resulting in the cell membrane taking longer to envelop the particle. Particle size can also 
lead stalling of the phagocytosis process and lead to the low phagocytosis rates we found 
for the 3 μm and 4.5 μm particles [99]. Smaller particles require the recruitment of fewer 
signaling components before their engulfment, providing for less time to be affected by 
inhibitory signals such as wortmannin, LY294002, or dominant-negative SHIP-1 [108, 
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109]. Furthermore, it has been suggested that there is a specific size threshold of 0.5-1 
μm whereby the macrophage phagocytosis transitions from a coated vesicle-mediated 
uptake into an actin-mediated uptake. While actin is crucial for the formation of the 
phagocytic cup, these reports suggest a size threshold of 2 μm before inhibitors that 
prevent Fc receptor signaling to the actin cytoskeleton are generated [56, 108, 109]. The 
action of size-dependent inhibitory signals would also account for why there exists a 
consistently low average number of microparticles per cell for the 3 μm and 4.5 μm 
particles regardless of Fc density.  It will be important to more fully understand these 
inhibitors if we hope to take advantage of the increased volume of delivery associated 
with internalization of larger particles. For example, nanoparticles are frequently touted 
as superior delivery method due to their greater surface area per unit volume compared to 
microparticles [37]. However, the volume of particles decreases with the third power of 
diameter, which is a detriment for delivering significant amounts of encapsulated drugs 
or imaging agents into the cell interior via nanoparticles.  
 Not only are these results relevant to the direct delivery of microparticles to 
macrophages, but they are also important to understanding the downstream effects of the 
internalization of these particles. This approach to immunoengineering will have a broad 
impact on drug delivery to macrophages as well as altering macrophage phenotype for a 
desired application. The recognition of immune threats can occur through physical cues 
or the many different biological receptors on the cell surface.  A major distinction 
between the different receptor pathways is the immune-activation state they induce in the 
macrophage. Receptors that bind to “self” products intended for waste removal will not 
trigger immune activation; those cells will simply increase in size (if necessary) and then 
engulf and degrade the recognized substance in a non-inflammatory process.  However, 
receptors that recognize substances that are potentially dangerous to the body (e.g. 
through PAMP-receptors or Fc receptors) will trigger activation of the macrophage, 
leading to secretion of immune mediators and enhanced intracellular degradative capacity 
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to deal with the active insult represented by the engulfed threat.  Opsonization of 
microparticles tends to favor activation of cells as it is a natural mechanism of targeting 
foreign substances for recognition and response, but will tend to not lead to full cellular 
activation in the absence of secondary “danger signals” [32, 56]. In the future we plan to 
examine how the size and Fc density of particles also affect cytokine production during 
and after phagocytosis, indicating changes in macrophage phenotype. As we investigate 
the activation of the immune system with Fc-functionalized particles, the inclusion of 
bioactive substances such as small-molecule drugs, antibiotics, cytokines or chemokines, 
or vaccine targets, either on or contained in the microparticles, could lead to a broad-
based immune delivery system that is tunable to experimental or clinical needs: one that 
could be either inflammatory or not; affect a broad or more targeted population of 
macrophage cells; or deliver small amounts of highly active substances, or larger 
amounts of less active materials. 
 The gene expression and secreted protein results from this study show that both 
particle size and Fc density coating have a strong impact on macrophage response. While 
the goal was to pinpoint exact shifts in macrophage phenotype as a result of particle size 
and Fc density coating, this was not easily apparent. This is not surprising as 
characterizing and classifying macrophage phenotype is a complicated and subjective 
field. As a whole, the gene expression levels for 0.5 μm particles coated with high levels 
of Fc showed an increase in M1 associated markers. This profile was not seen as clearly 
in the 1 μm particles. However, these expression levels were much lower than those in 
the LPS only group.  In fact, Fc particles were able to inhibit pro-inflammatory 
expressions levels in macrophages there first exposed to LPS. This then suggest a bias 
towards a M2b phenotype, which is often associated with immune-complexes. The M2b 
phenotype is often listed as having both pro- and anti-inflammatory effects. Our results 
suggest the 0.5 μm particles lead to a pro-inflammatory M2b phenotype while the 1 μm 
lead to an anti-inflammatory M2b phenotype when given alone.  
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 Previous studies have shown delivering particles coated in high levels of Fc 
resulted in a decrease of IL-12 and IL-10 [32] and macrophages treated with immune 
complexes are known to display a similar shift [1, 57]. This was not seen in our results as 
we saw an increase in IL-12 production with the exception of LPS treated groups. When 
high Fc density particles were added after LPS treatment, decreased levels of gene 
expression were seen for IL-12α and IL-12β. However decreased expression was also 
observed for IL-10. Further studies are needed to fully characterize the effects on secreted 
protein, such as ELISA analysis on conditioned media and evaluation at a longer time 
point of 24 hours. The lack of a longer time point may also explain the lack of correlation 
with previously published results as there may not have been enough time for 
macrophages to secrete protein in response to the stimulus of the particles. Previously 
published works have also used particles or erythrocytes that are greater than 2 μm in 
size. As we saw the 0.5 μm particles functionalized with high a Fc density coating 
elicited the strongest IL-12 secretions, this would suggest that the size of the particle 
plays a vital role in response. High levels of IL-12 were not seen in the 0.5 μm particles 
with low levels of Fc coating or the BSA only coated particles. This suggests a 
combination of high Fc coating and small particle size can reverse the suppression of IL-
12 production previously seen in immune-complex studies. The amount of TNFα 
secreted by the addition of 0.5 μm particles with high Fc density coatings, suggests a 
strong pro-inflammatory response. As in the case of IL-12, this was dependent on both 
particle size and Fc density. However further studies incorporating larger particles and 
longer time points will be needed to confirm these results. These experiments should also 
be repeated in bone marrow macrophages derived from mice deficient in FcRγ chain or 
wild type macrophages that first have their FcR blocked to show that these effects are 
dependent on FcRγ ligation.  
 If validated, these results would have a broad impact on the fields of biomaterials 
and immunomodulation with applications in cancer biology, pathogen-associated 
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infections, and vaccine development. This is due to these particles showing a slight shift 
to a pro-inflammatory response. However this pro-inflammatory state was never as 
severe as seen in the LPS treated groups, and in fact reduced the inflammatory state for 
those LPS treated groups. Fc coated particles could for example then be used to switch 
tumor associated macrophages into a more inflammatory state that could reverse the 
immunosuppressive environment around the tumor. [14, 48] The same can be said for 
intracellular bacterium, such as Mycobacterium tuberculosis, Leishmania major, and 
Listeria monocytogenes.[110] These smaller, high Fc coated particles could be used in 
conjunction with current drug regiments to not only delivery the drug, but to also activate 
the macrophage to fully degrade the bacterium and prevent it from continually spreading 
within the host.  
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 The body’s immune response is comprised of a vital system of cells and 
macromolecules that help to regulate homeostasis as well as respond to, kill, and clear 
invading pathogens or waste products [5, 8, 9, 29]. Components of the immune system 
have also been shown to play a role in a variety of disease processes such as cancer, [7] 
atherosclerosis, [46, 47] and numerous other autoimmune and immune deficiency 
diseases [4, 63, 64]. In total, chronic immune-related disease affects ~5% of the United 
States population each year, [111] highlighting the importance of developing a novel 
method for modulating the body’s immune response in a directed and “tunable” manner. 
The humoral immune response represents the body’s use of specific proteins, including 
immunoglobulins and complement components, to opsonize and/or inactivate invading 
pathogens while also initiating cytotoxic processes and recruiting immune cells through 
chemotaxis [3, 5, 112]. The complement system [13, 80, 113, 114] comprises a group of 
proteins that become enzymatically activated through one of three pathways: the 
classical, alternative, and lectin pathways [22, 23, 63, 64]. The classical pathway is 
activated by the binding of C1 monomers to closely apposed Fc regions of a single IgM 
or multiple IgG molecules, and formation of the C1 complex [115-117].  




 Adapted and Modified from Pacheco, Patricia M., et al. "Tunable complement activation by particles with 
variable size and Fc density." Nano LIFE 3.02 (2013). 
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 If one of these pathways is initiated by an invading pathogen, the complement 
proteins are activated in a cascading manner, resulting in the deposition of complement 
proteins on the surface of the pathogen and the formation of a membrane attack complex, 
also known as a terminal complement complex (TCC). The TCC forms a nanoscale 
transmembrane channel leading to loss of integrity of the bilayer membrane and osmotic 
lysis of the pathogen [22, 23]. Diffusion of the proteolytic fragments of these deposited 
complement components also interact with other immune cells, such as neutrophils and 
macrophages, to amplify the phagocytosis signal(s) and aid in the clearance of the 
targeted pathogen [23, 33, 63, 64]. While the complement system represents only a 
portion of the humoral response, any knockdown of complement component receptors 
severely impairs the overall humoral immune response [118].  In addition, the 
complement system is also involved in the transition to and effectiveness of the adaptive 
immune response, as successful complement activation has been shown to act as an 
adjuvant to improve vaccine effectiveness [12, 13]. 
 The interaction of micro- and nanoparticles with humoral immune constituents 
provides an opportunity to modulate the magnitude and location of the innate immune 
response. Particle induced immunomodulation can be accomplished through physical 
signals, such as particle size and shape; chemical signals, such as material composition; 
and biological signals, such as opsonization; resulting in an opportunity for rational 
design and control of an immune response suited for specific applications (i.e. a 
“tunable” immune response) [30, 67, 119-122]. Particles have previously been used in 
immune related applications as delivery platforms for vaccine development and in the 
study of phagocytosis [13, 24, 30, 119, 123]. In our phagocytosis studies, particles were 
coated in immunoglobulin gamma (IgG) antibody so that the crystallizable fragment (Fc) 
of the antibody is orientated outwards. This Fc portion of the antibody is then able to 
interact with Fc-receptors on the surface of immune cells to trigger receptor-mediated 
phagocytosis. Consistent with previous work, these studies demonstrate that the size of 
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the particle and the density of Fc can affect the efficiency of phagocytosis and cytokine 
production by macrophages [30, 31, 124].  However, in contrast to previous work, these 
studies established a minimum Fc coverage and a maximum size threshold for biological 
and physical stimulation of the complement cascade. 
 While the destruction of pathogens through lysis that results from the insertion of 
the membrane attack complex is typically seen as the traditional role of the complement 
system, recent studies have shown that it also plays a key role in the body’s response to 
tumors [23, 65, 66] and the effectiveness of vaccines [12, 13]. This only further 
highlights the need for a tunable design platform for location-specific complement 
system modulation. Despite the large role of Fc functionalized particles in the study and 
manipulation of macrophages, only a few studies have investigated Fc functionalized 
particles to understand their role in activating the complement system [13, 80, 113, 114]. 
Previous studies have found that particle size can affect complement system activation, 
possibly due to the physical effect of the curvature of small particles on complement 
constituent assembly [125-127]. The C1 complex assembles in direct contact with 
apposed Fc molecules, and is only stabilized and retained when the C1q head is bound 
multivalently to Fc molecules [128, 129]. Therefore, the density of Fc molecules on a 
particle, as well as their orientation, may also affect complement activation. While 
efficient activation of complement is an important defense against pathogens, 
uncontrolled activation may lead to “self” tissue damage [130]. Rationally designed 
modulation of the complement response will allow development of a wide range of 
therapeutic agents for many different immunopathologies. 
 We hypothesize that micro- and nanoparticles functionalized with IgG molecules 
orientated with the Fc regions outwards are capable of stimulating the complement 
system in a manner that depends upon the particle size and density of the opsonizing IgG 
antibody. Therefore by controlling these variables, we can modulate the complement 
system in a tunable manner. The design of micro- and nanoparticles for nanoscale control 
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of Fc stimulants may be useful as a clinical therapeutic agent to augment and modulate 
the immune response through the complement system.  
4.2 Materials and Methods 
4.2.1 Microparticle Opsonization 
 Carboxylated polystyrene particles of 0.5 μm, 1 μm, 2 μm, and 4 μm diameters 
were purchased from Polysciences (Warrington, PA) and Bangs Laboratories (Fishers, 
IN). An illustration representing the particle functionalization process is shown in Figure 
18. The particles were first incubated in a 2 mg/mL bovine serum albumin (BSA) (Sigma 
Aldrich, St. Louis, MO) solution to adsorb a saturating layer of BSA onto the surface of 
the particles. The amount of BSA added was increased with the total amount of particle 
surface area to keep the BSA coating on the particles uniform, in accordance with 
manufacturer’s recommendations. To confirm that the amount of BSA added was in fact 
saturating, we used fluorescently labeled BSA in increasing and decreasing 
concentrations. The fluorescence was then measured using a flow cytometer. This BSA 
coating serves to orient the Fc portion of the bound anti-BSA IgG molecules to the 
exterior. To vary the amount of exposed Fc domains on the particles, sheep polyclonal 
anti-BSA IgG antibody (Abcam, Cambridge, MA) was then added in various molar 
ratios. We began with a minimum molar ratio of 1:50 representing a single IgG molecule 
to every 50 BSA molecules that were originally added, creating a dilute surface density 
of Fc molecules on the particles. The ratio was then increased to a maximum of 2:1. To 
ensure a high density Fc coverage on the 4 μm particles, we also created two additional 
sets of particles coated with molar ratios of 5:1 and 10:1. For each functionalization step, 
we allowed the particles to incubate with the proteins for at least 2 hours at room 
temperature in phosphate buffered saline (PBS) at a pH ~7.2 (Invitrogen, Carlsbad, CA). 
After the incubation period, the particles were washed 3 times through centrifugation and 
PBS exchange. We also reserved a set of particles that were coated in only BSA. To 
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demonstrate that Fc density was varied successfully, we examined a sample of each 
particle condition through incubation with a fluorescently labeled rabbit anti-sheep IgG 
secondary antibody (Abcam, Cambridge, MA). The particles were then analyzed using a 
flow cytometer. The flow cytometer recorded the fluorescent intensity per particle and 
50,000 events were recorded for each condition, the mean fluorescent intensity represents 
the arithmetic mean for those events. The measured fluorescent intensity corresponds to 
Fc density on the particles.  
 
Figure 18: Microparticle functionalization process. 
 (A) Antigen is adsorbed onto the particle surface at a saturating density and then (B) IgG 
is added in increasing molar ratios and (C) to create particles with variable Fc density. 
 
4.2.2 Flow Cytometry 
 Measurement of Fc density on all particle samples was analyzed using a flow 
cytometer (BD Accuri C6, Franklin Lakes, NJ) after incubation with the fluorescently 
labeled secondary antibody. Fluorescence was measured with a 630 ± 30 nm bandpass 
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filter capable of detecting the fluorescent marker. The resulting mean fluorescent 
intensity (MFI) of the particle sample for each Fc density condition was calculated using 
the CFlowPlus software (BD, Franklin Lakes, NJ) and FlowJo (Tree Star, Inc., Ashland, 
OR). We also recorded the number of microparticles per mL to establish the particle 
concentration of each sample.  
4.2.3 Serum Collection 
 Whole blood was first collected from 2 healthy, consenting human donors with 
approval from the GIT IRB #H10011. Approximately 10 mL of whole blood was 
collected from each donor and was allowed to clot at 4°C. The samples were then 
centrifuged at 2,000 G for 10 minutes. The resulting serum from each sample was 
decanted and transferred to a sterile centrifuge tube. Centrifugation was repeated to 
remove any residual red blood cells, which resulted in approximately 5 mL of serum 
collected from each donor. For complement mediated cytotoxicity studies normal human 
serum was purchased (Quidel). This same normal human serum, as well C1 deficient, C4 
deficient and Factor B deficient serum purchased from Quidel were also used to 
characterize the complement pathways activated by our Fc particles.  
4.2.4 Complement Activation Assay 
 The MicroVue CH50 Enzyme Immunoassay (EIA) (Quidel) was used to evaluate 
the magnitude of complement activation as a result of the addition of Fc functionalized 
particles to human serum (Figure 19). This kit is used clinically to determine complement 
system deficiencies by measuring the amount of generated terminal complement 
complexes [131, 132]. Included in the kit is heat aggregated gamma globulin (HAGG) 
activator, which we use as a positive control. The kit was used according to the 
manufacturer’s instructions. Approximately 10-30 million particles were added to serum 
samples from both donors for each Fc density and particle size condition. The CH50 EIA 
measures the amount of TCC generated through the use of TCC specific antibodies. The 
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amount of antibody binding is directly correlated to the amount of fully formed TCC that 
results in 50% hemolytic lysis in accordance with the kit standards and quality control. 
Results are shown in CH50 unit equivalents per milliliter (CH50 U Eq/mL).  
 
 
Figure 19: Overview of CH50 EIA 
Microparticles, standards and controls are added to wells containing human serum. 
During incubation, C1 complex components present in the serum begin to bind to Fc 
regions and the resulting complex triggers the complement system cascade; this results in 
the generation of the terminal complement complexes (TCC). 
 
4.2.5 Monte Carlo Simulation of Complement Activation 
 To better examine the effect of Fc density on complement activation by Fc-coated 
particles, we modeled the surface assembly of the C1 complex via multiple immobilized 
Fc molecules, a critical step of complement activation. A Monte Carlo simulation [133] 
of antibodies randomly distributed on a gridded antigen-coated surface was modeled in 
MATLAB (MathWorks, Natick, MA). An N  N grid was created to represent a portion 
of the surface area of the particles. Each element of the grid represents a region of a 
single densely packed Fc molecule, formed by attachment of IgG antibody to surface-
immobilized antigens. We estimate each element to therefore correspond to a 18 nm  18 
nm square of the particle surface. A random number generator determined whether each 
element was occupied by a Fc molecule by assigning a value of “0” or “1” to each 
element on the grid. The probability of occupation was varied to simulate an increase in 
the amount of Fc on the surface. A total of 100 simulated surfaces were created to 
represent a range of Fc occupancy. Since the C1 complex binds multivalently to several 
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Fc molecules, we search for dense Fc regions by using a window of elements with a size 
equivalent to the fully-assembled C1 complex. We choose a window size of 3  3 
elements. The window was raster scanned over the entire grid to evaluate the number of 
regions which contain a threshold number Fc molecules or greater. We used a threshold 
value of 4 Fc molecules in the results. Since these regions will more potently initiate the 
assembly and stabilization of the C1 complex [130] and trigger enzymatic activation of 
subsequent complement signaling molecules, a complement activation metric was 
developed to quantify the number of dense Fc regions. The metric uses an algorithm to 
first identify regions that are Fc-dense, then counts the total number of those regions 
within the N  N grid. A variety of threshold numbers of Fc molecules were used to 
identify regions of sufficient density to contribute towards the complement activation 
metric. The algorithm prohibited double counting of high-density Fc regions by removing 
previously identified elements that contributed to the complement activation metric. After 
all elements in the grid were evaluated, we calculated the total complement activation by 
summing the number of Fc-dense regions. The simulation for each antibody occupancy 
percentage was repeated ten times and the results were averaged. A grid size of 15  15 
elements or greater all produced results that converged to a consistent complement 
activation metric when normalized to the fully occupied value.  
4.2.6 Complement Deposition Analysis 
 The amount of complement components deposited on the surface of high Fc 
density condition of 2:1 and BSA only coated particles, was determined in a similar 
manner as previously done by others [134]. Microparticles and serum, both normal 
human serum and C4 deficient serum, were incubated in the same concentrations used for 
the CH50 EIA. After the 1 hour incubation period, the particles and serum were collected 
and centrifuged at 1500 G for 10 minutes. The supernatant was decanted and replaced by 
a 5% sterile filtered milk solution. Particles were resuspended and allowed to incubate at 
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room temperature for 30 minutes to prevent any future non-specific binding. After the 
incubation period, the particles were centrifuged at 1500 G for 10 minutes and the milk 
solution decanted. The microparticles for each condition were split into 4 microcentrifuge 
tubes. Mouse anti-human antibodies for C1q, C3b, C4b, and Sc5b9 were added to each 
respective tube at a 1:25 dilution in accordance with manufacturer’s instructions. The 
particles and primary antibody were incubated at room temperature for 30 minutes. After 
incubation the particles were centrifuged as before and replaced with a AlexaFluor 488 
labeled donkey anti-mouse secondary antibody at a 1:2000 dilution in accordance with 
manufacturer’s instructions. The particles and secondary antibody were incuabated for 30 
minutes at room temperature protected from light. After the incubation period the 
particles were centrifuged again and replaced with a 1% PFA solution. Particles 
incubated in no serum and only incubated with the secondary antibody served as controls 
for non-specific binding of the primary and secondary antibody respectively. 
4.2.7 Complement Mediated Cytotoxicity Assay 
 A DH5α strain of Escherichia coli was used to evaluate if complement system 
activation from our particles could be applied towards directed complement mediated 
cytotoxicity. The strain was a gift of the lab of Dr. Craig Forest, by way of the lab of Dr. 
Brian Hammer. E. coli was plated on LB agar plates overnight. The following day 
individual colonies were collected and inoculated in 15 mL conical tubes containing LB 
broth. All bacteria were grown in a humidified incubator at 37ºC. The concentration of 
bacteria was calculated by taking the absorbance measurement at OD600 with a value of 
0.1 corresponding to 1E8 CFU/mL. Approximately 5E5 CFU were added per well of a 
96-well plate for all experiment conditions. For wells treated with particles, 
approximately 5E6 particles were add per well. Conditions with serum were treated with 
14 μL of human serum.  HAGG was added at 86 μL per as previously done. Isopropyl 
alcohol was added at a total concentration of 10% as a positive control for E. coli death.  
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The total volume of each well was adjusted to 125 uL with LB broth. The E. coli was 
allowed to incubate with each condition for 4 hours at 37ºC. After the incubation period, 
the contents of each well were stained with the Live/Dead BacLight Bacterial Viability 
kit (LifeTechnologies) in accordance with manufacturer’s instructions. The contents were 
then analyzed using flow cytometry.  
4.2.8 Statistical Analysis 
 Statistical analysis was conducted by using analysis of variance to determine 
significance of variables. Tukey- Kramer honestly significant difference (HSD) was used 
for post-hoc analysis to determine significance between each group.  
 
4.3 Results 
4.3.1 Increased Molar Ratio of Antibody Results in Increased Density of Fc 
 We evaluated the average Fc density per particle by measuring the mean 
fluorescent intensity (MFI) with flow cytometry (Figure 20 and Figure 21).  
Fluorescently tagged secondary antibody was used to quantify the relative Fc density per 
particle. For the particle sizes of 0.5 μm, 1 μm, 2 μm, and 4 μm, we measured the MFI for 
each of the Fc conditions, defined as the molar ratio of Fc to BSA antigen, for the values 
of: 2:1, 1:1, 1:5, 1:10, and 1:50. We also evaluated the highly-saturated molar ratios of 
5:1 and 10:1 for the 4 μm particle. As the Fc density was increased, the measured MFI of 
the particles also increased. We also evaluated the MFI of BSA-only particles and saw 
minimal fluorescence at each particle size.  
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Figure 20: MFI for each Fc density condition across the different particle sizes used 
for this study.  
 
 
Figure 21: Normalized MFI to particle surface area and the maximum Fc condition 
of 2:1.  
Confirms that as the Fc density increases, the normalized MFI increases as well. The MFI 
for each Fc condition and particle size was first normalized by the particle surface area 
and then normalize to the value for the Fc density of 2:1.   
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4.3.2 Effects of Particle Size on Complement Activation 
 The effect of particle size on complement system activation was determined by 
evaluating the amount of CH50 equivalents produced as a result of particles coated at the 
2:1 Fc density condition (Figure 22). The complement system was successfully activated 
using Fc-functionalized particles of size 0.5 μm, 1 μm, 2 μm, and 4 μm. For all but the 4 
μm particle sizes, CH50 equivalents were generated at comparable levels to the HAGG 
activator. We found that equivalent numbers of 4 μm particles generated significantly 
decreased levels of complement activation than the smaller sized particles (p<0.01).  
 
Figure 22: Effect of particle size on complement system activation.  
*, significantly different from HAGG control (p<0.01); N=4. 
4.3.3 Complement System Activation Depends on Fc Density 
 To better understand our results concerning the effects of particle size (Figure 22), 
the various sized particles were used to evaluate the effects of Fc density on complement 
system activation. We tested three Fc density conditions, corresponding to a molar ratio 
of Fc:BSA of 2:1, 1:1, and 1:5 for all particle sizes, as well as particles coated in BSA-
only. In addition, to ensure maximal Fc coverage of the 4 μm particles, 5:1 and 10:1 
ratios were also tested. HAGG activator was our positive control. Our results showed a 
remarkable dependence of complement activation on Fc density for all particle sizes 
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(Figure 23 and Figure 24).  For the 0.5 μm, 1 μm, and 2 μm particle sizes, the 2:1 
condition, representing a high Fc density, successfully activated the complement system 
and produced levels of CH50 equivalent to or surpassing the positive HAGG control. In 
all cases, the 1:1 condition shows a level of complement activation significantly above 
background (p<0.05), but below the 2:1 complement activation levels. The 1:5 and BSA-
only particles did not activate the complement system efficiently, as the amount of CH50 
equivalents generated was significantly lower than the positive control (p<0.005) as well 
as the high Fc density conditions of 1:1 (p<0.05) and 2:1 (p<0.001). Therefore, Fc 
density is a significant dependent variable in complement system activation. 
 
 
Figure 23: Effect of Fc density and particle size on complement system activation.  
*, significantly different (SD) from HAGG (p<0.005); ♦, SD from 2:1 Condition 




 We observed that for the 4 μm particles, the 2:1 Fc condition did not fully activate 
the complement system to the level seen in other functionalized particles or in the 
positive control. To test whether this lack of efficient complement system activation was 
due to insufficient antibody binding to the particle surface, we also evaluated the effect of 
higher amounts of added IgG [5:1 and 10:1 ratios (Figure 24)]. Despite the increased 
amount of Fc used to functionalize the particles, we did not observe increased levels of 
CH50 equivalent activation. This result indicates that 4 μm particles activate complement 
at lower levels than other particle sizes not because a lack of saturating Fc, but for a 
reason related to particle size. 
 
Figure 24: Fc density on larger particles does not affect complement system 
activation.  
*, significantly different from HAGG (p<0.001); N=8 replicates (N=16 replicates for 
HAGG) 
4.3.4 High Fc Density Particles Activate the Classical and Alternative Complement 
Pathways 
 To determine through which complement pathway activation was proceeding, we 
tested two different complement deficient sera. C1 deficient serum allowed us to evaluate 
alternative pathway activation and Factor B deficient allowed us to evaluate classical 
pathway activation. Our results show that the HAGG activator resulted in comparable 
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amounts of complement activation in the Factor B deficient serum as was seen in normal 
human serum. However HAGG activation levels were greatly diminished in the C1 
deficient serum, indicating the importance of the classical pathway. A similar pattern was 
observed in the 0.5 µm and 1 µm high Fc density particles, however, in the C1 deficient 
serum, the high Fc density particles are capable of activating significantly greater levels 
of complement compared to the HAGG control, indicating a partial utilization of the 
alternative pathway (Figure 25). This is not strictly an effect of the material properties of 
the particles, as there was only minimal expression of complement in the BSA only 
coated particles in the Factor B and C1 deficient serum (Figure 26).   
 
Figure 25: Complement system activation in normal, Factor B deficient, and C1 





Figure 26: High Fc density microparticles successfully activate complement system 
in Factor B and C1 deficient serum.  
 
4.3.5 Complement Deposition on Particle Surfaces 
 We have shown that high Fc density coated particles are capable of activating the 
complement system. To further understand Fc particle-mediated activation of 
complement, we measured the deposition of activated complement components on the 
particle surface. Using flow cytometry analysis, we first set our positive gate based on the 
“no serum” treated conditions as a control for non-specific binding. We then calculated 
the average percentage of events that were positive for each complement component 
(Figure 27). We found that 40-50% of the particles were positive for C3b, a component 
that is needed for activation in all pathways. This was the most common complement 
component found on the particles. SC5b9, an analog to TCC, was the next most common 
component found on the particles with approximately 30% of the particles averaging as 
positive. There were minimal levels of C1q and C4b components found on the particles.   
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Figure 27: Complement deposition on high Fc coated particles.  
 
 As it was expected for C1q to be highly present on the particles due to the 
classical complement system activation, the complement deposition protocol was 
repeated with C4 deficient serum. This would prevent any deposited C1q from being 
further catalyzed and possibly removed from the particle surface. We found that the 
percentage of particles positive for C1q approximately tripled when incubated in C4 
deficient serum (Figure 28). 
 




4.3.6 Monte Carlo Simulation of Complement Activation 
 To estimate the appropriate window size for determining a threshold Fc density, 
we compared the size of closely packed antibody-antigen complex, represented by each 
element in the grid, to the C1 complex size. While individual BSA molecules occupy a 
linear distance of 7 nm [135], electron microscopy analysis of BSA-antibody complexes 
determined an average root mean square end-to-end distance of 18 nm [136, 137]. We 
acknowledge that these measures are only to illustrate an estimate for the dimension of 
the grid, as antibody antigen binding regions are flexible [138]. The linear dimension of 
the binding region of the C1 complex is determined by the reach of two flexible C1q 
arms of 18.5 nm length each and a fibril-like stalk of width 4.5 nm [115]. The total 
diameter is approximately 41 nm, though the specific geometry may vary due to the 
orientation of the globular c-terminal regions [139]. Microscopic analysis of antibody 
complexes and assembled C1q structures on opsonized lipid vesicles show C1 complex 
size ranging between 50 nm to 100 nm [140, 141]. Comparing the element size of 18 nm 
to the size of a C1 complex, which ranges from 41 nm to over 50 nm, we determine that a 
window of 3  3 elements most closely approximates the spatial reach of the C1 complex.   
 To determine the threshold number of Fc molecules necessary to assemble a C1 
complex, we note that the affinity for the assembled C1 complex to Fc molecules 
increases dramatically in the case of multimers of Fc molecules [129]. Clq monomers 
show only weak binding, in the range of micromolar affinity, to the Fc regions of isolated 
IgG. However multiple, closely-spaced Fc molecules, such as those in immune 
complexes to repetitive molecular motifs, increase the binding of multivalent Clq a 
thousand-fold and enhance affinity to the few nanomolar [115, 128, 129, 142]. In our 
model of complement activation, we varied the number of Fc molecules within the 3  3 
window in order to contribute to the complement activation metric.  
 Based upon our experimental data, the activation of the complement system by 
Fc-functionalized micro and nanoparticles did not increase in a manner proportional to Fc 
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density, but instead showed a minimum threshold of density. To develop a model of 
complement activation by micro/nanoparticles, we performed a Monte Carlo simulation 
of the complement system activation process that captures the need for a local high 
density of Fc molecules to initiate C1 complex formation and the subsequent classical 
complement cascade products. This model assumed an array of antibody binding sites 
and included a probability of antibody binding at any given site, as shown in a schematic 
in Figure 29A. A grid of elements was generated, in which each element corresponds to a 
site of possible antigen-antibody complex formation and therefore presentation of Fc. A 
random number generator determined the binding of the antibody to the antigen. An 
example of a result of the antibody binding and Fc display over a grid is shown in Fig. 
Figure 29B. In this example, the grid contains 15  15 elements and the probability of 
each element containing a Fc molecule is 20%, which is represented as a “1” in each grid 
element. A 20% occupancy percentage nominally corresponds to the condition of 1:5 
molar ratio of antibody to BSA. The probability of antibody bound at each element 
corresponds to the amount of surface area covered by antibodies for a sufficiently large 
grid. In this example we identified by red boxes dense Fc clusters as 4 or more molecules 
inside the 3 X 3 window, and therefore likely sites of complement activation through C1 
complex formation. An activation metric was calculated for the grid at each occupancy 
percentage and plotted in Figure 29C.  The results of the activation metric revealed a very 
low activation value for an occupancy of 0-20%, with a dramatic increase for higher 
occupancy values, consistent with requirement of C1 multivalency. As we expected, a 
high probability of antibody binding corresponded to a saturated complement activation 
value. Other threshold values of Fc within the window of elements were also tested. 
Values of 3 or greater most accurately fit the experimental data. 
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Figure 29: Monte Carlo simulation of complement system of activation. 
(A) A schematic of packed antigens (spheres) and partial surface coverage of antibodies 
(Y’s) displaying Fc binding sites. A C1 complex assembles on regions of high Fc density, 
identified by dark filled spheres, contributing to complement activation. (B) Monte Carlo 
grid of 15 x 15 elements, where the probability of antibody binding at each element is 
20% and displayed as a “1” in each grid element. An algorithm has identified 4 regions of 
dense Fc clusters outlined in red, which contribute to the complement system activation 
metric. (C) A complement activation metric calculates the number of regions of high Fc 
density. Very low activation is seen below 20% occupancy with a dramatic increase at 
high occupancy values.  
 
4.3.7 Complement Mediated Cytotoxicity 
 Bactericidal activity is a primary function of complement in vivo, therefore we 
studied the effect of our Fc coated particles towards complement mediated cell 
cytotoxicity. Flow cytometry was used to analyze the percentage of dead E. coli for each 
condition in accordance with manufacturer’s recommendations. As preliminary 
experiments showed that the fluorescence used to stain live cells also absorbed onto the 
surface the particles, we used yellow-green fluorescent carboxylated particles. The 
fluorescence from these particles is so strong, that a side scatter gate in conjunction with 
the green fluorescence filter was used to gate out the particles. We were then able to gate 
around the live and dead stained E. coli. Our results show that complement components 
present within the normal human serum result in approximately 30% E. coli death and 
percentage of dead bacterium was reduced in heat inactivated serum. This result indicates 
that serum is inherently bactericidal through complement pathways. [143] The HAGG 
positive control used in complement system activation assays resulted in less E. coli 
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death than the serum only control. As expected, the addition of IPA resulted in very high 
levels of E. coli death. (Figure 30)  
 
Figure 30: Percentage of E. coli death as a result of control conditions.  
With heat inactivated serum (HIS), normal human serum (S), heat aggragated gamma 
globulin (HAGG), isopropyl alcohol (IPA). *, significantly different from all conditions, 
p<0.05; †, significantly different from E. coli only and E. coli + HAGG, p<0.05 using 
ANOVA and Tukey HSD (N=5) 
 
 The addition high Fc density particles alone resulted in low levels of E. coli death, 
suggesting that the particles alone are not cytotoxic. Adding normal human serum to E. 
coli and Fc particle treated conditions lead to increased amounts bacterium death. There 







Figure 31: Percentage of E. coli death as a result of high Fc coated particles. 
With normal human serum (S), (N=5) 
4.4 Discussion 
 The immune system is a vital and intricate system necessary for the clearance and 
defense against invading pathogens, as well as to maintain systemic homeostasis [5, 8, 9, 
29]. Therefore, the ability to initiate, direct, and/or modulate the immune system could 
prove to be an important means to treat and prevent multiple immune-related disorders 
[4, 7, 46, 47, 63, 64, 111]. The complement system has been shown to play a role not 
only in immune-specific diseases [63, 64], but in vaccine efficacy [13] and inhibition of 
tumor growth [65, 66]. By using micro- and nanoparticles, we have adapted a well-
established method previously used to study other immune components [13, 24, 26, 30, 
94] to the activation and modulation of the complement system.  
 We successfully varied the density of Fc presentation on the particles by varying 
the molar ratio of IgG added to particles coated with BSA. Our results showed that Fc 
density has a significant impact on the magnitude of complement activation. While 
several studies have shown that multiple IgG molecules are needed to efficiently activate 
the classical complement pathway, none have examined the effect of Fc density when 
displayed on micro- and nanoparticles. Our results from the complement component 
 75 
deficient sera and complement deposition study further characterize the complement 
system activation resulting from high Fc density coated particles. 
 It is surprising that an Fc density of 1:5 did not successfully activate the 
complement system for any of the particle sizes. A 1:5 antibody:antigen ratio nominally 
represents 20% surface coverage, although the measured coverage varies from 15% to 
35% as determined from flow cytometry (Figure 20). For uniformly distributed antibody 
of 20% surface coverage, a Monte Carlo simulation calculated average spacing between 
Fc molecules as approximately 2.1 element spaces, corresponding to a separation of 38 
nm if we assume an antibody-antigen complex size of 18 nm. However, due to stochastic 
variation in the antibody binding, each particle will on average contain a significant 
amount of surface area that locally displays a sufficiently high density of Fc to activate 
complement. Our model has determined that the proportion of the particle surface with a 
high local density of Fc increases nonlinearly with the surface coverage, as seen in Fig. 
7C. This result suggests a possible explanation for the observed nonlinearity of 
complement activation with Fc density. We hypothesize therefore that an essential trigger 
for complement activation by Fc-coated particles is the assembly of the C1 complex on 
the surface of the particles via binding to multiple, closely apposed Fc molecules. Our 
model is meant to only illustrate the importance of Fc density in nonlinearly activating 
complement, as it neither accounts for possible confounding effects such as antibody 
aggregation on the particle surface, Fc orientation due to particle surface curvature, nor 
other factors that may trigger or inhibit complement activation. 
 While high Fc density conditions activated the complement system for all the 
tested particle sizes, the size of the particle played a significant role in determining the 
magnitude of the activation. For the 0.5 μm and 1 μm particles, there is no complement 
response for low density of Fc, but immune stimulation increases dramatically to a 
plateau at higher Fc density values. The 2 μm particle supports a more tunable platform 
for complement activation. For the 2 μm particles, only the highest Fc density condition 
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of 2:1 activated the complement system at comparable levels to the HAGG activator. The 
next highest Fc density condition of 1:1 activated the complement system in significantly 
lower levels than the HAGG activator (p<0.005), but it was still higher than the 1:5 and 
BSA-only condition (p<0.05). This apparent switch from a binary-like response in 
smaller particles to a tunable response in mid-range sized particles further highlights the 
importance of particle size to complement system response. Larger 4 μm particles 
showed an even less efficient complement activation response. Even at the highest 
antibody levels tested (10:1), complement activation plateaued at less than half of the 
positive HAGG control.  
 This result is all the more surprising considering the number of particles was held 
constant for each of the experimental conditions during the activation study. Remarkably, 
when we consider the amount of complement system activation by Fc-functionalized 
particles per unit surface area, the dependence on particle size is even more clearly 
demonstrated. It might be expected that complement system activation would be 
proportional to the surface area of beads and the absolute degree of Fc presentation. 
Instead, we found that the complement activation per unit area was over 4 orders of 
magnitude larger for the 0.5 μm beads compared to the 4 μm beads. In addition, a power 
law function describes the relationship between complement activation per unit area of 
each particle and particle size, with an exponential dependence of −2.5 (Figure 8). This 
effect results from the combination of lower maximum complement activation for larger 
particles, as well as an increased surface area of the larger beads. Previous work has 
shown that an increase in polymer surface area results in an increase in complement 
system activation [80, 126]. Our work thus suggests that functionalization of particles 




Figure 32: Maximum measured complement activation per μm
2
 of particles versus 
particle size. 
 
 This study represents the first time that polymeric particles artificially coated in 
Fc were used to activate the complement system. While previous studies had suggested 
that crosslinking of multiple Fc molecules was the only requirement for initial activation 
by the classical pathway, our results suggest that the presence of multiple Fc regions is 
not sufficient to fully activate complement. In our studies, we observed that the 
complement system response decreases with increasing particle size, for a given Fc 
density condition. The sensitive dependence of the complement response on Fc density 
indicates the importance of nanoscale effects in efficiently modulating the response and 
that particle size can be an independent means to adjust the level of complement response 
once a threshold of Fc density is attained. While we cannot rule out a possible 
confounding effect in which particles prepared with similar treatments produce unequal 
Fc densities, the effect of particle size on complement activation may also be due to 
inherent biological properties of the complement system.  
 The topographic curvature of IgM-functionalized particles and peptidoglycan 
layers has been shown to influence the strength of complement activation, potentially 
through changes of the orientation of the Fc molecules. This same group found that 
complement system activation was maximized for 250 nm particles with decreased 
activation for both larger and smaller particle sizes. However, as they used IgM 
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antibodies to dextran already present in human serum samples and did not 
prefunctionalize their particles, these results could not be used to determine the impact of 
particle size on complement and the preference of IgM binding to particles of different 
size. As IgM are sufficient to activate complement, this method also does not allow the 
tuning of complement activation, either through variation in Fc density or through 
particle size, especially in the micron scale. [126] We cannot currently say whether the 
observed effect is due to the influence of surface curvature, the decrease of diffusive 
motion leading to increased depletion of reactants, or to some other effect.  However, 
regardless of the reason, the observed inefficiency of complement activation with 4 μm 
beads could lead to the development of complement-modulation therapeutic agents, while 
nanoscale particles are likely more suited to more fully activating complement.  
 The results of our complement mediated cytoxicity assays are a proof of concept 
for future studies for directing complement system activation. Future experiments are 
needed to determine if there is a saturation level for particle mediated complement 
system activation and if this will correlate with cell death. These results could then be 
applied to biomedical needs in which controlled cell death is required such as for drug-
resistant infections and cancer. However, these efforts will need to be balanced against 
the possible effect of increased inflammation as cleaved complement components act as 
powerful chemokines.  
 Better understanding the variables involved in successful complement system 
activation will improve our ability to take advantage of nanotechnology in basic or 
applied immunology. Due to the powerful nature of successful complement system 
activation, as well as the multiple naturally-occurring safeguards in place to prevent an 
autoimmune response, the observed dependence on particle size and Fc density affirms 
our hypothesis of the importance of nanoscale effects on complement control. As the 
complement system response is essential for clearance of pathogens and vaccine efficacy, 
the ability to modify and/or fine-tune the magnitude of complement system activation 
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with nanotechnology holds significant promise in these broad reaching fields. However, 
further study is needed to adequately delineate and fully understand the effects of particle 
size and Fc density, as well as to further identify the specific range of Fc presentation 
needed to successfully activate the complement cascade. 
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CHAPTER 5  INTERACTIONS OF Fc OPSONIZED 
MICROPARTICLES AND BCG WITH MACROPHAGES  
5.1 Introduction 
 Bacillus Calmette-Guerin (BCG) is the sole FDA approved vaccine for the 
prevention of active tuberculosis due to Mycobacterium tuberculosis infection. The BCG 
vaccine was considered very effective upon its release in 1920s, but overtime various 
studies have shown a wide range in efficacy from 0-80%. While there seems to be a 
considerable protective effect on young infants and studies in mice, this protection can 
wane dramatically in cases of adult pulmonary infection. The high rates of initial 
infection, as well as the increasing number of multi-drug resistant tuberculosis infections, 
highlight the need for an improved tuberculosis vaccine. [19, 21, 49] There are many 
suggested reasons behind this wide range in efficacy.  One is the loss of immunogenic or 
virulent factors of the vaccine, which is a live strain of Mycobacterium bovis, as it was 
passaged over time. Another includes the exhaustion of the local immune response due to 
the lack of clearance of the vaccine due to T cell depletion over time. This would suggest 
that increased uptake of the vaccine after initial delivery and increasing the local immune 
response may increase vaccine efficacy. Others have shown that the vaccine does not 
interact with local macrophages upon injection. [82] 
 There are currently a multitude of different approaches to solve these 
shortcomings of the vaccine such as developing a variety of subunit vaccines, addition of 
adjuvants, or using a particle based delivery platform. [144-148] With the goal of 
targeting intracellular pathogens, which typically evade the lysosome, to the macrophage 
lysosome to ensure full degradation, one group primed macrophages with Fc coated 
particles. The Fc particles crosslinked the Fc receptors on the macrophage surface and 
triggered downstream internal cell signaling that led to the recruitment of LAMP1. This 
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causes the lysosome to mature and results in pathogen degradation. [62] However, the 
need to deliver the particles an hour before the vaccine would be difficult to implement 
clinically. Therefore, we set out to show that delivering Fc particles and BCG together, 
would lead to increased internalization of BCG and targeting of BCG to the mature 
lysosome. We chose two particle sizes, 0.5 µm and 1 µm, based on our successful results 
from previously published studies that showed increased levels of phagocytosis and 
complement system activation for these sizes. [149, 150] While this would have a 
significant application in vaccine efficacy, there are also applications for treatment of 
tuberculosis and other intracellular pathogens that evade lysosome maturation.  
5.2 Materials and Methods 
5.2.1 Cell Culture 
 Mycobacterium bovis, Bacillus Calmette-Guerin (BCG) Pasteur strain, was 
originally purchased from ATCC. Cultures were initially plated on 7H10 agar plates. 
These agar plates were composed of Middlebrook 7H10 agar with a 10% oleic acid, 
albumin, dextrose, and beef catalase (OADC) supplement. After approximately 4 weeks, 
colonies were collected and inoculated into Middlebrook 7H9 broth supplemented with 
sodium pyruvate and a 10% albumin, dextrose, and beef catalase (ADC).  More 
information on the specific reagent formulations can be found in Appendix A.2.1. 
Cultures were grown for an additional 4 weeks before use in phagocytosis experiments. 
All cultures were grown in a humidified incubator at 37ºC.  
 Prior to use in experiments, a sample of the liquid culture was centrifuged for 10 
minutes at 3000 G. The broth was then decanted and replaced with PBS. The mixture was 
then briefly vortexed and then sonicated. After sonication, the mixture was then passed 
through a 22 gauge syringe, in order to ensure single cell suspension.  The concentration 
of liquid cultures was determined in accordance with previously published methods. A 
spectrophotometer was used to measure the OD580 with an absorbance reading of 0.1 
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corresponding to 6.7E7 colony forming units (CFU) per mL. RAW 264.7 murine 
macrophages were cultured as outlined in Section 3.2.2. BCG was stained with TxRd on 
a shaker table for 45 minutes. The TxRd BCG was then washed twice through 
centrifugation and PBS to remove any unbound stain. 
5.2.2 Microparticle Opsonization 
 Both yellow-green fluorescent and non-fluorescent polystyrene microparticles 
were used and were opsonized as outlined in Sections 3.2.1 and 4.2.1.  
5.2.3 Phagocytosis 
 Phagocytosis assays were conducted using a similar protocol as outlined in 
Section 3.2.3. Approximately 500,000 RAW 264.7 macrophages were plated per well in 
a 6-well plate in complete, serum supplemented DMEM media and allowed to incubate 
overnight. Autoclaved coverslips were added to each well prior to cell plating if 
microscopy was to be done.  Prior to phagocytosis experiments, the wells were washed 
with phosphate buffered saline solution and then refilled with 0.5 mL of DMEM alone. 
For the BCG alone and BCG with microparticles conditions, approximately 10 CFUs of 
BCG per macrophage were added per well. For microparticle only conditions, 
approximately 20 particles were added per macrophage while only 10 particles per 
macrophage were added for BCG with microparticles conditions. The following 
microparticle sizes were tested using both a high Fc density ratio of 2:1 (antibody to 
antigen) and BSA only conditions: 0.5 µm, 1 µm, and 4 µm. The phagocytosis incubation 
ranged from 2 hours, for microscopy analysis, and 4 hours, for flow cytometry analysis, 
at 37ºC in a humidified incubator with 5% CO2.  Following the incubation period, the 
content of each well was decanted. The well was then washed with PBS twice to remove 
any unattached microparticles or bacteria. 
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5.2.4 Microscopy 
 To characterize the effects of test conditions on lysosome maturation, we used 
two different fluorescent schemes. We first attempted a commercially available 
fluorescent stain called Lysosenor (Life Technologies). Lysosensor has been used in 
previous studies to stain only the lysosome and the fluorescence of the stain increases as 
the lysosome becomes more acidic. This stain was added immediately after the cells were 
washed as this is a live cell stain. Multiple concentrations were tested to determine the 
optimal amount for image analysis. The wells were then imaged directly using a Nikon 
Epi-Fluorescence inverted microscope.  
 Our second method involved immunofluorescence using a primary antibody for 
the lysosome maturation marker LAMP-1 followed by an AlexaFluor488 conjugated 
secondary antibody (Abcam). DAPI was used to stain the nucleus as outlined in Section 
3.2.5. To fix the cells, a 4% paraformaldehyde (PFA) solution was added to each well for 
10 minutes. The wells were then washed twice with PBS. A permeabilazation solution, 
comprised of 0.1% TritonX and PBS, was added for 30 minutes at room temperature. The 
solution was then decanted and a 5% BSA blocking solution was then added for another 
30 minutes at room temperature. After washing the wells twice, the primary antibody 
solution was added and allowed to incubate overnight at 4°C. The wells were then 
washed 3 times, before adding the secondary antibody solution. After 30 minutes at room 
temperature and protected from light, the wells were washed 3 times and then the DAPI 
solution was added for 5 minutes. The coverslips were then transferred to glass slides 
treated with an anti-fade solution, outlined in Section 3.2.5, and sealed with nail polish. 
The slides were then imaged using a Zeiss 710 Confocal microscope.  
5.2.5 Flow Cytometry 
 Following the phagocytosis incubation period and washing steps, 0.5 mL of PBS 
was added to each well. The cells were then detached from the plate surface by scraping 
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and transferred to a microcentrifuge tube.  Flow cytometry was then conducted as 
outlined in Section 3.2.4.  
5.2.6 Nitric Oxide Assay 
 To determine the amount nitric oxide produced by the macrophages as a result of 
the microparticles and/or BCG, we used a commercially available Griess assay 
(Promega). For this, we tested the decanted media from the phagocytosis experiments at 
4 hours or 24 hours. The assay was performed in accordance with manufacturer’s 
instructions and the resulting absorbance was measured at 535 nm using pathlength 
correction.  
5.3 Results 
5.3.1 Microparticles Lead to Increased Levels of BCG Phagocytosis 
 Flow cytometry was used calculate the percentage of macrophages positive for 
BCG as well as the relative amount of BCG associated with each macrophage. The 
macrophage population was initially gated from non-internalized BCG and/or particles 
and other cellular debris. This macrophage population was then plotted along the forward 
scatter and the TxRd fluorescent channel. The untreated macrophages, or cells only, 
condition was used to gate cells that were negative for BCG by setting a threshold on the 
TxRd fluorescent channel. Examples of the gating used are shown below (Figure 33). 
The mean fluorescent intensity of the TxRd labeled BCG was also recorded of the entire 
macrophage population and for the BCG positive gated population.  
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Figure 33: Example of flow cytometry gating scheme used to determine BCG 
positive macrophages.  
 
 Our flow cytometry results show an increase in the percentage of macrophages 
that were positive for BCG when microparticles were added during incubation and this 
was further confirmed using fluorescence microscopy (Figure 34). The median 
percentage of macrophages associated with BCG, when BCG was delivered alone, was 
approximately 15%. When high density Fc coated particles were added, for both 0.5 µm 
and 1 µm, that number more than double to 42% and 43%, respectively. However, BSA 
only coated particles also resulted in similar levels of BCG positive macrophages. There 
was no significant difference in the percentage of BCG positive cells between the Fc 
coated particles and BSA only coated particle treated conditions. While these particle 
treated conditions did result in an increase of overall percentage of macrophages positive 
for BCG, there was large variation between replicates. Therefore there was no significant 





Figure 34: Microparticles added with BCG lead to increased levels of BCG 
internalization.  
Fluorescent microscopy shows (A) the amount of BCG associated with macrophages 
when delivered alone compared to (B) when delivered with 1 µm 2:1 high Fc density 
coated particles. (C) Shows that adding microparticles, Fc coated or BSA only, leads to 
increases in the percentage of macrophages positive for BCG. (N>6)  
 
 We then measured the mean TxRd fluorescent intensity for the BCG positive 
macrophages to determine if fewer macrophages were internalizing greater levels of BCG 
(Figure 35). There was no significant difference in mean fluorescent intensity across any 
of the particle and BCG treated macrophages or the BCG only treated macrophages. To 
determine if there were small amounts of BCG below our gating threshold we also 




36). We found that the median value of the MFI for the BCG only group was slightly 
lower than the particle and BCG treated groups.  None of these results were significantly 
different from each other.  
  
 
Figure 35: Mean TxRd fluorescent intensity of BCG positive macrophages.  
 
 




 As we saw that Fc coating on the particles did not impact the amount of BCG 
internalized, we repeated our experiments with a larger 4 µm particle that was coated 
only in BSA. We have previously shown that macrophages do phagocytose 3 µm and 4.5 
µm in great numbers. Therefore this allowed us to evaluate if the increase in BCG 
positive cells was a result of smaller, more easily phagocytosable particles or an 
additional foreign presence. Our results show that the 4 µm BSA only coated particles 
with BCG and the 0.5 µm 2:1 high Fc density coated particles with BCG treated 
macrophages had similar levels of BCG positive macrophages (Figure 37). Repeating our 
analysis on the mean TxRd fluorescent intensity showed no significant changes across the 
different treatment groups (Figure 38).  
 
Figure 37: Percentage of BCG positive macrophages when treated with 4 µm BSA 




Figure 38: Mean fluorescent intensity of 4 µm BSA coated and BCG treated 
macrophages.  
MFI of (A) BCG positive macrophages and (B) all treated macrophages.  
 We also determined whether macrophages needed to be primed with Fc coated 
particles before adding BCG. The macrophages were pretreated with either BCG or 0.5 
µm 2:1 Fc coated particles for one hour, before the 0.5 µm 2:1 Fc coated particles or 
BCG, respectively, were added to the wells. The total amount of time the BCG was 
allowed to incubate with the macrophages was kept constant at 4 hours. BCG only and 
0.5 µm 2:1 Fc coated particles with BCG were used as comparisons. We found there was 
no significant difference between the percentage of BCG positive macrophages for any of 
the tested populations (Figure 39).  
 
Figure 39: Percentage of BCG positive cells when macrophages are pretreated with 
BCG or Fc coated particles.  
It should be noted that these results are preliminary with N=2 
A) B) 
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5.3.2 Fc Microparticles with BCG Result in Increased Nitric Oxide Production 
 Nitric oxide production was measured after 4 hours and 24 hours. After 4 hours, 
there was a slight increase in nitric oxide production in macrophages treated with BCG 
compared to the macrophage only group. Adding 1 µm 2:1 Fc coated particles led to a 
greater increase in nitric oxide and this increase was maintained in the presence of BCG 
(Figure 40A).  For the 24 hour treated groups, an LPS treated group was added as a 
positive control while a 1 µm BSA coated particle was added as a negative control. After 
24 hours, the differences between the particle and BCG treated groups were minimal 
(Figure 40B). There were significantly low levels of nitric oxide in the untreated 
macrophage only group. The concentration of nitric oxide was slightly lower in the BCG 







Figure 40: Nitric oxide production macrophages treated by BCG and 1 µm Fc 
coated particles.  
Concentration of nitric oxide after (A) 4 hours (N=3) and (B) 24 hours (N=4). *, 
significantly different from MΦ only, p<0.05, using ANOVA with Tukey HSD.  
5.3.3 No Correlation with the Addition of Fc Microparticles with BCG and 
Lysosome Maturation  
 Confocal microscopy was used to image the distribution of the LAMP-1 through 
BCG and BCG with particle treated cells (Figure 41). These images show that LAMP-1 
is more distributed in treated macrophages compared to untreated macrophage controls. 
However, there was a not a strong correlation between LAMP-1 colocalization with BCG 
in macrophages treated with BCG alone or with BCG and 1 µm or 0.5 µm 2:1 Fc coated 
particles. There was also no correlation between LAMP-1 intensity for any of the treated 









Figure 41: Representative confocal images of BCG and lysosome staining.  
This shows BCG stained in red and LAMP-1 stained in green with blue representing the 
nucleus of (A) macrophages treated with 0.5 µm 2:1 Fc coated particles with BCG and 
(B) BCG only. 
5.3.4 Microparticles and BCG Are Less Likely to be Phagocytosed Together 
 As there was no correlation with lysosome maturation, we then analyzed our 
images to determine the amount of treated macrophages that were positive for both 
particles and BCG. Clusters of particles as well as BCG could be detected using 
brightfield microscopy. BCG could also be detected with the 534 nm laser. LAMP-1 
expression was imaged using a 488 nm laser. We found that the majority of macrophages 
positive for particles, were not positive for BCG (Figure 42). The percentage of 
macrophages that were positive for particles, BCG, or both was quantified by counting 
the cells from confocal microscopy images. Images from macrophages that were treated 
with 1 µm 2:1 Fc particles and BCG at the same time or were treated with 0.5 µm 2:1 Fc 
particles for one hour and then BCG was added. The results show that the percentage of 
macrophages positive for BCG stayed constant at approximately 30%.  When 




macrophages were primed with Fc particles first, the percentage of macrophages positive 
for both BCG and beads increased from 10% to 20%. The amount of LAMP-1 expressed 
did not seem to vary, whether the cell phagocytosed BCG and/or particles or did not. 
Macrophages that phagocytosed large number of particles appeared to form a large 
vacuole around the particles that was lined with LAMP-1 expression. 
 
Figure 42: Confocal microscopy shows macrophages are not likely to be positive for 
both particles and BCG.  
(A) Overlap of brightfield, green fluorescence, and red fluorescence filters (B) Overlap of 
green fluorescence and blue fluorescence (C) Overlap of brightfield and red fluorescence 
with white arrows pointing to clusters of internalized particles. Shows macrophages that 
phagocytosis large numbers of particles do not phagocytosis large amounts of BCG. 
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Exceptions are noted by the two cells circled in black. Arrows point at cells with large 
numbers of particles (D) Red fluorescent filter showing amount of BCG phagocytosed 
 
 
Figure 43: Percentage of macrophages positive for beads, BCG, or both.  
A) Macrophages were treated with 1 µm 2:1 Fc beads and BCG or B) macrophages were 
treated with 0.5 µm 2:1 Fc beads first for one hour before BCG was added.  
5.4 Discussion 
 While these results were not expected and seem to reject the hypothesis, we have 
made observations that pose a multitude of additional questions for future studies. It was 
thought that the addition of Fc coated microparticles to BCG would result in increased 
phagocytosis and lysosome maturation as shown in previous studies [62]. However, our 
results suggest that it is the addition of the just the microparticle alone, whether 
functionalized with Fc or coated in BSA only, that leads to greater levels of phagocytosis. 
That this result was seen in 0.5 µm, 1 µm, and 4 µm particles, suggest microparticle size 
was not a significant variable. While the Fc coating, or lack thereof, did not significantly 
affect the percentage of macrophages positive for BCG, this does not mean biochemical 
signals were not a factor.  We have previously shown that the addition of microparticles, 
both Fc and BSA coated, affects cytokine expression and secretion (Sections 4.3.5 and 
3.3.6). Therefore we can assume the complicated feedback loop of cytokine signaling 
between macrophages that have phagocytosed particles and/or BCG plays a significant 
role in BCG phagocytosis. One method to test for this in future experiments would be to 
A) B) 
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use conditioned media from macrophages treated with Fc coated particles. We can also 
repeat gene expression analysis on Fc coated particle and/or BCG treated macrophages.  
 Our results also showed that there was no change in mean fluorescent intensity of 
BCG positive macrophages. This suggests that the macrophages internalizing BCG in the 
presence of particles are doing so at the same level of BCG only treated macrophages. 
Overall more BCG is thus internalized by the macrophages in the particle treated 
conditions. This increase in the amount of BCG internalized would correspond to 
increased clearance of the vaccine and interaction of BCG with macrophages as an 
antigen presenting cell. If the macrophages do fully process the BCG for antigen 
presentation then the bacterium is also destroyed. This would also show that our particles 
may be used as an antibiotic to enhance macrophage destruction of tuberculosis and resist 
residency of the bacteria intracellularly. Our particles could then be used as a supplement 
to current treatments and use patient’s own immune system to clear the infection.  
 To prevent unnecessary repeated experiments on multiple variables, there is a 
need for better understanding of how these particle based immune complexes interact 
with macrophages in the presence of BCG. Previous studies have shown that mice 
deficient in the Fcγ chains increased the susceptibleness of the animal to infection and 
increased an immunosuppressive response [151]. The previous work with Fc coated 
particles and BCG with the resulting increase in lysosome maturation had two different 
conditions that my work. One, they used 2 µm particles, and two, they first primed the 
macrophages with the Fc coated particles before adding BCG. [62] Our results show no 
difference between groups that were first primed with Fc coated particles or BCG. If the 
increase in lysosome maturation was in part due to the particle size, this would suggest 
the macrophage may be more receptive to particles that are approximately on the same 
size scale as BCG. The 4 µm that we tested may fall just beyond the upper boundary for 
size mediated enhanced BCG uptake. Therefore we can repeat our experiment using 2 
µm particles or rod shaped particles in order to better mimic BCG. We can also compare 
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these results to BCG opsonized with IgG and Fc coated particles that are first bound to 
BCG.  
 We also attempted to answer how the addition of Fc coated particles might 
reverse many of the immunosuppressive characteristics of tuberculosis [152] and its 
analogous form in BCG. Induction of nitric oxide has been shown to lead to increased 
BCG death [153] which is why we wanted to quantify the amount our particles induced. 
We found that initially there was approximately a 30% increase as a result of our 
particles, but this difference diminished overtime. Further evaluation will be needed to 
determine if a small increase in nitric oxide production after initial treatment is enough 
for full vaccine clearance. However these results may be promising in vivo as the initial 
nitric oxide production may affect the response of macrophages recruited to the site of 
tuberculosis infection and prevent the infection from spreading within these newly arrive 
hosts. This also goes back to activating macrophages so they are better capable of fully 
processing the bacterium, whether it is the vaccine grade or an actual infection. Previous 
studies have shown the addition of LPS to macrophages before adding BCG lead to 
increased clearance of the bacterium. [154] While this supports the argument that priming 
macrophages into a pro-inflammatory state will result in better clearance of the 
bacterium, this is not an ideal candidate for vaccine implementation. The strong response 
LPS provides will likely lead to cytotoxic effects and a severe reaction in patients. If our 
Fc coated particles prove to provide an attenuated inflammatory response, either through 
macrophage or complement system activation, the may still prove to be a viable option.  
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CHAPTER 6  CONCLUSIONS AND FUTURE DIRECTIONS 
 The field of immunology has always been a broad and impactful. The more recent 
field of immunoengineering allows us to not only modify the immune response, but to 
purposefully engineer a response for a desired application. The humoral immune 
response is not only a front line defender against invading pathogens, but also strongly 
impacts the adaptive immune response. The Fc region is a powerful immunomodulator 
within the humoral response and using this fragment in various surface densities allows 
us to attempt to control the immune response. Microparticles are an ideal platform as a 
number of variables can be controlled and tested. Certain properties, such as the material 
of the particle, can then be changed in the future depending on the application while 
keeping other variables, such as size and coating, the same. This work has shown that 
microparticles coated with various Fc densities can have a strong impact on macrophage 
and complement system response.  
6.1 Fc Density and Microparticle Size Effect Macrohpage Phagocytosis and 
Phenotype 
 Our results in CHAPTER 3 show that both Fc density and microparticle size have 
a strong affect on macrophage response. Smaller microparticles (0.5 μm and 1 μm) 
coated in high densities of Fc led to the greatest number of particles internalized per cell. 
The larger particles (3 μm and 4.5 μm) resulted in significantly lower levels of 
internalized particles, but the greatest amount of volume of internalized particle per cell. 
These results suggest particle size and Fc density can be varied for different goals of drug 
delivery applications. If the goal of the delivery is to deliver the greatest number of 
particles or provide a stronger initial input to macrophages, then smaller particles would 
be ideal. However if the goal is to deliver the greatest amount of payload, then larger 
particles are preferred. There are limitations to this study, as the Fc pathway was never 
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blocked or inhibited to ensure that phagocytosis was FcR mediated. Future studies should 
be done to confirm FcR mediated phagocytosis, as well as a better understanding of the 
kinetics of internalization. Time-lapse microscopy can be used to determine how particles 
are internalized and if certain macrophages become more activated than others.  
 The results from the gene expression and cytokine secretion analysis shows that 
the size and Fc density of the particle affects macrophage response. This was true even 
when the particle sizes were what we previously considered small at 0.5 µm and 1 µm. 
The most powerful results were seen in the macrophages that were first treated with IL-4 
and LPS as the response was inverted when Fc coated particles were added. This reverse 
of macrophage response was seen even though the original stimulus of IL-4 and LPS was 
not removed from the media. The reverse in response for both alternative and classically 
activated macrophages suggest that Fc coated particles induce a phenotype that lies 
between these two states. Further work is needed to confirm this through expanded 
cytokine secretion analysis and expanding the incubation period. The increased levels of 
TNFα and IL-12 with the addition of high Fc density particles suggests a more pro-
inflammatory response. While TNFα production has been associated with increased FcR 
crosslinking, previous work has shown that levels of IL-12 production typically 
decreases. This could be an effect of particle size and most studies used larger particles or 
immune complexes alone. However, the amount of IL-12 produced may still be lower 
than IL-10 which would be in accordance with previous work. Repeating ELISA analysis 
with a proper dilution would provide further context. For future biomaterials applications, 
it would be important to understand if the gene expression and cytokine secretion levels 
are a result of the act of internalization or FcR crosslinking or combination of the two. 
This could be decoupled by coating a substrate with Fc ligands so the macrophages could 
bind but not phagocytose the complex. These results would be important for in vivo 
testing as a particle or substrate based platform, such as a hydrogel, could be delivered. 
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These results could then be applied to in vivo models where a shift in macrophage is 
desired such as chronic inflammation or sepsis.  
6.2 Fc Coated Microparticles Successfully Activate the Complement System 
 Chapter 4 showed the complement system could be activated by Fc coated 
particles and the level of activation could be controlled by changing the particle size and 
Fc density. This represents the first instance to our knowledge in which complement 
system activation has been achieved through Fc coated particles. While the majority of 
the resulting complement activation was through the classical pathway, a significant 
portion was also through the alternative pathway. This suggests the high Fc coated 
particles will be able to activate the complement system in vivo even in cases where a 
person is deficient in C1. However, there were significant lower levels of complement 
activation for larger particles. While curvature has been suggested to play a role in 
complement activation for unopsonized materials, it is not well understood why the larger 
particles failed to activate complement. Further studies are needed to understand why this 
occurred. One possibility would be that the 4 µm particles provide more surface area for 
initial complement components to deposit. The disperse spread of the initial components 
may prevent the cascade from completing. This could be tested by diluting the amount of 
4 µm particles so that the total surface area of is equivalent to that of the 0.5 µm and 1 
µm used previously. It also important to understand the minimal amount of particles 
needed for complement system activation to prevent toxic autoimmune effects.  
 However, our proof of principle for inducing cytotoxic effect on E. coli showed 
only a modest increase in bacterial death compared to the inherent bactericidal properties 
of serum. While our complement deposition results showed that some of the activated 
complement components deposited on the cell surface, a portion likely remained in 
solution. As our EIA kit did not separate the particles from serum when determining the 
amount TCC formed, we cannot confirm the exact proportion deposited on particles 
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versus solution. By repeating the complement EIA on serum that has particles removed 
first, we could determine the amount of TCC free to deposit on potential in vivo surfaces. 
In the case of E. coli cytotoxicity, complement activation was not sufficient to result in 
bacterial death in significantly greater amounts than serum only conditions. The 10:1 
bead to bacterium was used as a proof of principle and is unlikely to be feasible clinically 
with the current particle sizes used. However the beads would show greater promise in 
the case of serum-resistant bacteria or in the case of complement deficient patients. 
[143]Further study is needed to determine if particle concentration, as well as decreased 
particle size, affects complement system activation and complement mediated 
cytotoxicity. In addition, we hypothesize that a Janus particle capable of directly binding 
a bacterium while activating the complement may lead to enhanced and selective 
cytotoxicity. Beyond cytotoxicity, complement system activation can be used to harness 
the powerful chemotactic effects of cleaved complement components C3a and C5a. 
Transwell migration assays can be performed to determine if Fc particle mediated 
complement activation leads to increased recruitment of various immune cells. We can 
also begin applying our Fc coated particles to known vaccine in vivo models to determine 
if an adjuvant effect is present.     
6.3 Microparticles Affect BCG and Macrophage Response 
 In Chapter 5 we attempted to show that Fc coated particles would lead to increase 
phagocytic activity of macrophages as well as increased lysosome maturation. However, 
the addition of a microparticles, no matter their protein coating, led to increased levels of 
phagocytosis. It is unlikely that it is the size of the particle, as there was also no 
difference when larger 4 µm particles were added. This suggests the addition of particles 
alone triggers macrophages to become more phagocytic of BCG.  However as previous 
research has shown particles treated with 2 µm particles resulted in increased 
phagocytosis of BCG as well as increased lysosome mature, a repeated study with 2 µm 
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may be warranted. Previous work by others and work demonstrated in Chapter 2 showed 
that shows 2 µm particles may be ideal for triggering phagocytosis, particularly due to 
topographical characteristics of macrophages.   
 The amount of nitric oxide produced and LAMP-1 expression was also not 
significantly different between BCG and Fc particle treated conditions. While this was 
discouraging, a critical observation was made relating to colocalization of BCG and Fc 
coated microparticles. Macrophages that internalize high numbers of Fc coated 
microparticles did not internalized BCG and vice versa. This should be further examined 
and confirmed using flow cytometry. In this case, it should be noted that microparticles 
that are previously labeled with fluorescence will overpower any signal from TxRd 
labeled BCG. The use of conditioned media from macrophages treated with Fc coated 
particles can be used to determine if the increased phagocytosis of BCG is due to 
cytokine signaling. Microfluidic technology can then be used to carry out qRT-PCR on 
invidual macrophages. This could show the differences in macrophage response between 
macrophage that internalize BCG versus Fc coated particles. To ensure these responses 
are mediated through Fc pathways, macrophages deficient in FcR should be used as a 
negative control.  
 Repeated phagocytosis experiments will be carried out that label earlier 
components of the lysosome maturation pathway, such as β-actin, Rab5, Rab7, and PI3P. 
This would show when the lysosome maturation process stalls during internalization of 
BCG and how the delivery of Fc coated particles affects each maturation step. Another 
method for determining lysosome maturation is by determining the amount of BCG 
degraded within the lysosome. Treated macrophages will be lysed with the lysate plated 
on agar plates to determine the viable CFUs. This would have broad implications on 
vaccine development as well a method for clearance of infection.  
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6.4 Perspective 
 This thesis showed the humoral immune response can be tuned using 
microparticles of various size and Fc coating density (Table 3). The phagocytosis results 
not only provide a greater understanding of how the combined effect of Fc density and 
particle size have on particle internalization, but we have also generated a particle 
internalization “toolbox” through which future researchers can tune particle variables to 
achieve desired applications. Quantifying macrophage phenotype is a complicated field, 
but the completed gene expression results provide a guide that will allow researchers to 
focus on genes that significantly modulate. This also suggests that macrophage plasticity 
can be altered upon delivery of a particle based system. The ability to alter macrophage 
response after initial priming will benefit a variety of pathologies including 
atherosclerosis, sepsis, allergy, and wound healing. Controlled complement system 
activation is significant to the immunology field, as this is the first time complement 
activation occurred through Fc coated particles. The complement system cannot be 
overlooked within the biomaterials field as complement system activation may be 
affecting the host response in a manner that is unexpected, such as increased cell death. 
These results also show the complement system can be activated through multiple 
pathways by Fc coated particles which is important to consider for patients who may be 
deficient in a single pathway components. The results from incubation of Fc coated 
particles and BCG with macrophages show that direct interaction of particles with 
macrophages is not needed for uptake in BCG. This highlights the importance of 
paracrine signaling that can be harnessed for altering macrophage response.  
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Table 3: Summary of effects of Fc density and particle size on macrophage and 






  Macrophages represent a powerful but complicated system which can be altered 
via particles after initial activation. Controlled complement system activation can be 
achieved and exploited in a variety of applications including vaccine development and 
chemotaxis. The results from this work can be applied to the greater fields of biomaterials 
and immunoengineering in hopes of better understanding important physical and 
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A.1. Supplemental Information for Microparticle Internalization 
A.1.1. Protein Levels Used for Particle Coating 
 







A.1.2. Verification of Fc Coating on Particles 
 
Figure A 2: Normalized mean fluorescence intensity of yellow-green fluorescent 
microparticles labeled with TexasRed fluorescently conjugated secondary 
antibodies.  
Decreasing normalized MFI corresponds to decreased Fc density for fluorescent particles, 
however there is evidence of possible non-specific absorption of the secondary antibody 













A.1.4.  Additional Quantification of Internalized Particles 
 
Figure A 4: Surface area of particles internalized per cell for different 
functionalizations.  
The total surface area of internalized particles by macrophages for different particle 






Figure A 5: Volume of particles internalized per cell for different functionalizations. 
The total volume of internalized particles by macrophages for different particle 
sizes and Fc densities. BSA-only particles are shown for comparison. 
A.2. Supplemental Information for Mycobaterium bovis Interactions 
A.2.1. Mycobacterium bovis culture 
 To create the Middlebrook 7H10 agar plates, 19 g of Middlebrook 7H10 agar was 
added to a flask containing 900 mL of deionized water and 5 mL of glycerol. This 
mixture was then stirred over a hotplate until the agar dissolved. The flask and contents 
were autoclaved and then cooled to approximately 55ºC. The OADC supplement was 
composed of 0.05 g of oleic acid, 5 g of bovine albumin, 2 g dextrose, and 0.004 g of 
beef catalase. This supplement was then added to 100 mL of deionized water and 0.85 g 
of sodium chloride. After the supplement fully dissolved, the solution was sterile filtered 
before adding it to the agar mixture. The supplement agar was then poured into 100 cm 
sterile petri dishes.  
 To create the Middlebrook 7H9 broth, 4.7 g of Middlebrook 7H10 agar and 4.4 g 
of sodium pyruvate was added to a flask containing 900 mL of deionized water and 2 mL 
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of glycerol. This mixture was then stirred over a hotplate until the broth dissolved. The 
flask and contents were autoclaved and then cooled to approximately 55ºC. The ADC 
supplement was composed of 5 g of bovine albumin, 2 g dextrose, and 3 mg of beef 
catalase. This supplement was then added to 100 mL of deionized water. After the 









1. Mosser, D.M. and J.P. Edwards, Exploring the full spectrum of macrophage 
activation. Nature Reviews Immunology, 2008. 8(12): p. 958-969. 
2. Anderson, J.M., A. Rodriguez, and D.T. Chang, Foreign body reaction to 
biomaterials. Seminars in Immunology, 2008. 20(2): p. 86-100. 
3. Tan, T.T. and L.M. Coussens, Humoral immunity, inflammation and cancer. 
Current Opinion in Immunology, 2007. 19(2): p. 209-216. 
4. Smith, D.A. and D.R. Germolec, Introduction to immunology and autoimmunity. 
Environmental health perspectives, 1999. 107 Suppl 5: p. 661-5. 
5. Parkin, J. and B. Cohen, An overview of the immune system. Lancet, 2001. 
357(9270): p. 1777-89. 
6. Parkin, J. and B. Cohen, An overview of the immune system. Lancet, 2001. 
357(9270): p. 1777-1789. 
7. Finn, O.J., Cancer immunology. The New England journal of medicine, 2008. 
358(25): p. 2704-15. 
8. Delves, P.J. and I.M. Roitt, The immune system. Second of two parts. The New 
England journal of medicine, 2000. 343(2): p. 108-17. 
9. Delves, P.J. and I.M. Roitt, The immune system. First of two parts. The New 
England journal of medicine, 2000. 343(1): p. 37-49. 
10. Girard-Pierce, K.R., et al., A novel role for C3 in antibody-induced red blood cell 
clearance and antigen modulation. Blood, 2013. 122(10): p. 1793-801. 
11. Suresh, M., et al., Complement component 3 is required for optimal expansion of 
CD8 T cells during a systemic viral infection. Journal of Immunology, 2003. 
170(2): p. 788-794. 
12. Stager, S., et al., Natural antibodies and complement are endogenous adjuvants 
for vaccine-induced CD8+ T-cell responses. Nature medicine, 2003. 9(10): p. 
1287-92. 
13. Reddy, S.T., et al., Exploiting lymphatic transport and complement activation in 
nanoparticle vaccines. Nature biotechnology, 2007. 25(10): p. 1159-1164. 
14. Sica, A., et al., Macrophage polarization in tumour progression. Seminars in 
Cancer Biology, 2008. 18(5): p. 349-355. 
15. Mosser, D.M., The many faces of macrophage activation. Journal of Leukocyte 
Biology, 2003. 73(2): p. 209-212. 
16. Martinez, F.O., L. Helming, and S. Gordon, Alternative Activation of 
Macrophages: An Immunologic Functional Perspective. Annual Review of 
Immunology, 2009. 27: p. 451-483. 
17. Gordon, S., Alternative activation of macrophages. Nature Reviews Immunology, 
2003. 3(1): p. 23-35. 
18. Kigerl, K.A., et al., Identification of two distinct macrophage subsets with 
divergent effects causing either neurotoxicity or regeneration in the injured 
mouse spinal cord. The Journal of neuroscience : the official journal of the 
Society for Neuroscience, 2009. 29(43): p. 13435-44. 
19. Flynn, J.L., Immunology of tuberculosis and implications in vaccine development. 
Tuberculosis, 2004. 84(1-2): p. 93-101. 
 113 
20. Flynn, J.L., J. Chan, and P.L. Lin, Macrophages and control of granulomatous 
inflammation in tuberculosis. Mucosal Immunology, 2011. 4(3): p. 271-278. 
21. Skeiky, Y.A.W. and J.C. Sadoff, Advances in tuberculosis vaccine strategies. 
Nature Reviews Microbiology, 2006. 4(6): p. 469-476. 
22. Sim, R.B. and S.A. Tsiftsoglou, Proteases of the complement system. Biochemical 
Society transactions, 2004. 32(Pt 1): p. 21-7. 
23. Ricklin, D., et al., Complement: a key system for immune surveillance and 
homeostasis. Nature immunology, 2010. 11(9): p. 785-97. 
24. Reddy, S.T., M.A. Swartz, and J.A. Hubbell, Targeting dendritic cells with 
biomaterials: developing the next generation of vaccines. Trends in Immunology, 
2006. 27(12): p. 573-579. 
25. Peppas, N.A. and R. Langer, New challenges in biomaterials. Science, 1994. 
263(5154): p. 1715-20. 
26. Mitragotri, S. and J. Lahann, Physical approaches to biomaterial design. Nature 
Materials, 2009. 8(1): p. 15-23. 
27. Kou, P.M. and J.E. Babensee, Macrophage and dendritic cell phenotypic diversity 
in the context of biomaterials. Journal of Biomedical Materials Research Part A, 
2011. 96A(1): p. 239-260. 
28. David, S. and A. Kroner, Repertoire of microglial and macrophage responses 
after spinal cord injury. Nature Reviews Neuroscience, 2011. 12(7): p. 388-399. 
29. Gordon, S. and P.R. Taylor, Monocyte and macrophage heterogeneity. Nature 
reviews. Immunology, 2005. 5(12): p. 953-64. 
30. Champion, J.A., A. Walker, and S. Mitragotri, Role of particle size in 
phagocytosis of polymeric microspheres. Pharmaceutical research, 2008. 25(8): p. 
1815-1821. 
31. Gallo, P., R. Goncalves, and D.M. Mosser, The influence of IgG density and 
macrophage Fc (gamma) receptor cross-linking on phagocytosis and IL-10 
production. Immunology Letters, 2010. 133(2): p. 70-77. 
32. Mosser, D.M., P. Gallo, and R. Goncalves, The influence of IgG density and 
macrophage Fc (gamma) receptor cross-linking on phagocytosis and IL-10 
production. Immunology Letters, 2010. 133(2): p. 70-77. 
33. Carroll, M.C., The complement system in regulation of adaptive immunity. Nature 
immunology, 2004. 5(10): p. 981-6. 
34. Yoon, J., K.J. Lee, and J. Lahann, Multifunctional polymer particles with distinct 
compartments. Journal of Materials Chemistry, 2011. 21(24): p. 8502-8510. 
35. Standley, S.M., et al., Acid-degradable particles for protein-based vaccines: 
Enhanced survival rate for tumor-challenged mice using ovalbumin model. 
Bioconjugate Chemistry, 2004. 15(6): p. 1281-1288. 
36. Loomis, K., K. McNeeley, and R.V. Bellamkonda, Nanoparticles with targeting, 
triggered release, and imaging functionality for cancer applications. Soft Matter, 
2011. 7(3): p. 839-856. 
37. Kohane, D.S., Microparticles and nanoparticles for drug delivery. Biotechnology 
and bioengineering, 2007. 96(2): p. 203-9. 
38. Aderem, A. and D.M. Underhill, Mechanisms of phagocytosis in macrophages. 
Annu Rev Immunol, 1999. 17: p. 593-623. 
 114 
39. Underhill, D.M. and A. Ozinsky, Phagocytosis of microbes: complexity in action. 
Annu Rev Immunol, 2002. 20: p. 825-52. 
40. Stout, R.D. and J. Suttles, Functional plasticity of macrophages: reversible 
adaptation to changing microenvironments. Journal of Leukocyte Biology, 2004. 
76(3): p. 509-513. 
41. Laskin, D.L., B. Weinberger, and J.D. Laskin, Functional heterogeneity in liver 
and lung macrophages. J Leukoc Biol, 2001. 70(2): p. 163-70. 
42. Hoeffel, G., et al., Adult Langerhans cells derive predominantly from embryonic 
fetal liver monocytes with a minor contribution of yolk sac-derived macrophages. 
J Exp Med, 2012. 209(6): p. 1167-81. 
43. Schulz, C., et al., A lineage of myeloid cells independent of Myb and 
hematopoietic stem cells. Science, 2012. 336(6077): p. 86-90. 
44. Medzhitov, R. and C.A. Janeway, Innate immunity: Impact on the adaptive 
immune response. Current Opinion in Immunology, 1997. 9(1): p. 4-9. 
45. Fearon, D.T. and R.M. Locksley, The instructive role of innate immunity in the 
acquired immune response. Science, 1996. 272(5258): p. 50-3. 
46. Hansson, G.K. and P. Libby, The immune response in atherosclerosis: a double-
edged sword. Nature reviews. Immunology, 2006. 6(7): p. 508-19. 
47. Ross, R., Atherosclerosis--an inflammatory disease. The New England journal of 
medicine, 1999. 340(2): p. 115-26. 
48. Sica, A. and V. Bronte, Altered macrophage differentiation and immune 
dysfunction in tumor development. Journal of Clinical Investigation, 2007. 117(5): 
p. 1155-1166. 
49. Andersen, P. and T.M. Doherty, The success and failure of BCG - implications for 
a novel tuberculosis vaccine. Nature Reviews Microbiology, 2005. 3(8): p. 656-
662. 
50. Armstrong, J.A. and P.D. Hart, Response of Cultured Macrophages to 
Mycobacterium-Tuberculosis, with Observations on Fusion of Lysosomes with 
Phagosomes. Journal of Experimental Medicine, 1971. 134(3): p. 713-&. 
51. Bhatt, K. and P. Salgame, Host innate immune response to Mycobacterium 
tuberculosis. J Clin Immunol, 2007. 27(4): p. 347-62. 
52. Mantovani, A., et al., The chemokine system in diverse forms of macrophage 
activation and polarization. Trends in Immunology, 2004. 25(12): p. 677-686. 
53. Dandrea, A., et al., Stimulatory and Inhibitory Effects of Interleukin (Il)-4 and Il-
13 on the Production of Cytokines by Human Peripheral-Blood Mononuclear-
Cells - Priming for Il-12 and Tumor-Necrosis-Factor-Alpha Production. Journal 
of Experimental Medicine, 1995. 181(2): p. 537-546. 
54. Heyman, B., Regulation of antibody responses via antibodies, complement, and 
Fc receptors. Annual review of immunology, 2000. 18: p. 709-37. 
55. Ravetch, J.V. and S. Bolland, IgG Fc receptors. Annual Review of Immunology, 
2001. 19: p. 275-290. 
56. Swanson, J.A. and A.D. Hoppe, The coordination of signaling during Fc 
receptor-mediated phagocytosis. Journal of leukocyte biology, 2004. 76(6): p. 
1093-1103. 
 115 
57. Sutterwala, F.S., et al., Selective suppression of interleukin-12 induction after 
macrophage receptor ligation. The Journal of experimental medicine, 1997. 
185(11): p. 1977-85. 
58. Anderson, C.F. and D.M. Mosser, Cutting edge: biasing immune responses by 
directing antigen to macrophage Fc gamma receptors. Journal of immunology, 
2002. 168(8): p. 3697-701. 
59. Mosmann, T.R. and R.L. Coffman, TH1 and TH2 cells: different patterns of 
lymphokine secretion lead to different functional properties. Annual review of 
immunology, 1989. 7: p. 145-73. 
60. Abbas, A.K., K.M. Murphy, and A. Sher, Functional diversity of helper T 
lymphocytes. Nature, 1996. 383(6603): p. 787-93. 
61. Aderem, A. and D.M. Underhill, Mechanisms of phagocytosis in macrophages. 
Annual Review of Immunology, 1999. 17: p. 593-623. 
62. Joller, N., et al., Antibodies protect against intracellular bacteria by Fc receptor-
mediated lysosomal targeting. Proceedings of the National Academy of Sciences 
of the United States of America, 2010. 107(47): p. 20441-20446. 
63. Walport, M.J., Complement. Second of two parts. The New England journal of 
medicine, 2001. 344(15): p. 1140-4. 
64. Walport, M.J., Complement. First of two parts. The New England journal of 
medicine, 2001. 344(14): p. 1058-66. 
65. Markiewski, M.M. and J.D. Lambris, Is complement good or bad for cancer 
patients? A new perspective on an old dilemma. Trends in Immunology, 2009. 
30(6): p. 286-292. 
66. Markiewski, M., et al., Modulation of the anti-tumour immune response by 
complement. Molecular immunology, 2008. 45(16): p. 4151-4151. 
67. Kumar, M.N.V.R., Nano and microparticles as controlled drug delivery devices. 
Journal of Pharmacy and Pharmaceutical Sciences, 2000. 3(2): p. 234-258. 
68. Champion, J.A. and S. Mitragotri, Role of target geometry in phagocytosis. 
Proceedings of the National Academy of Sciences of the United States of 
America, 2006. 103(13): p. 4930-4. 
69. Swartz, M.A., S.T. Reddy, and J.A. Hubbell, Targeting dendritic cells with 
biomaterials: developing the next generation of vaccines. Trends in Immunology, 
2006. 27(12): p. 573-579. 
70. Hubbell, J.A., S.N. Thomas, and M.A. Swartz, Materials engineering for 
immunomodulation. Nature, 2009. 462(7272): p. 449-460. 
71. Kwon, Y.J., et al., In vivo targeting of dendritic cells for activation of cellular 
immunity using vaccine carriers based on pH-responsive microparticles. 
Proceedings of the National Academy of Sciences of the United States of 
America, 2005. 102(51): p. 18264-18268. 
72. Dinauer, N., et al., Selective targeting of antibody-conjugated nanoparticles to 
leukemic cells and primary T-lymphocytes. Biomaterials, 2005. 26(29): p. 5898-
5906. 
73. Zauner, W., N.A. Farrow, and A.M. Haines, In vitro uptake of polystyrene 
microspheres: effect of particle size, cell line and cell density. J Control Release, 
2001. 71(1): p. 39-51. 
 116 
74. Tollis, S., et al., The zipper mechanism in phagocytosis: energetic requirements 
and variability in phagocytic cup shape. Bmc Systems Biology, 2010. 4. 
75. Badylak, S.F., et al., Macrophage Phenotype as a Determinant of Biologic 
Scaffold Remodeling. Tissue Engineering Part A, 2008. 14(11): p. 1835-1842. 
76. Yoshida, M. and J.E. Babensee, Poly(lactic-co-glycolic acid) enhances 
maturation of human monocyte-derived dendritic cells. Journal of Biomedical 
Materials Research Part A, 2004. 71A(1): p. 45-54. 
77. Bartneck, M., et al., Induction of specific macrophage subtypes by defined micro-
patterned structures. Acta Biomaterialia, 2010. 6(10): p. 3864-3872. 
78. Chonn, A., P.R. Cullis, and D.V. Devine, The Role of Surface-Charge in the 
Activation of the Classical and Alternative Pathways of Complement by 
Liposomes. Journal of Immunology, 1991. 146(12): p. 4234-4241. 
79. Montdargent, B., D. Labarre, and M. Jozefowicz, Interactions of functionalized 
polystyrene derivatives with the complement system in human serum. Journal of 
biomaterials science. Polymer edition, 1991. 2(1): p. 25-35. 
80. Montdargent, B., et al., Complement Activation and Adsorption of Protein-
Fragments by Functionalized Polymer Surfaces in Human Serum. Biomaterials, 
1992. 13(9): p. 571-576. 
81. Andersson, J., et al., Binding of C3 fragments on top of adsorbed plasma proteins 
during complement activation on a model biomaterial surface. Biomaterials, 
2005. 26(13): p. 1477-1485. 
82. Abadie, V., et al., Neutrophils rapidly migrate via lymphatics after 
Mycobacterium bovis BCG intradermal vaccination and shuttle live bacilli to the 
draining lymph nodes. Blood, 2005. 106(5): p. 1843-1850. 
83. Harding, C.V. and W.H. Boom, Regulation of antigen presentation by 
Mycobacterium tuberculosis: a role for Toll-like receptors. Nature Reviews 
Microbiology, 2010. 8(4): p. 296-307. 
84. Gordon, S. and P.R. Taylor, Monocyte and macrophage heterogeneity. Nature 
Reviews Immunology, 2005. 5(12): p. 953-964. 
85. Hodge, S., et al., Azithromycin increases phagocytosis of apoptotic bronchial 
epithelial cells by alveolar macrophages. Eur Respir J, 2006. 28(3): p. 486-95. 
86. Harris, M., Monoclonal antibodies as therapeutic agents for cancer. Lancet 
Oncology, 2004. 5(5): p. 292-302. 
87. Akewanlop, C., et al., Phagocytosis of breast cancer cells mediated by anti-MUC-
1 monoclonal antibody, DF3, and its bispecific antibody. Cancer Research, 2001. 
61(10): p. 4061-4065. 
88. Gallucci, S. and P. Matzinger, Danger signals: SOS to the immune system. Curr 
Opin Immunol, 2001. 13(1): p. 114-9. 
89. Trinchieri, G., Interleukin-12: a proinflammatory cytokine with 
immunoregulatory functions that bridge innate resistance and antigen-specific 
adaptive immunity. Annual review of immunology, 1995. 13: p. 251-76. 
90. Mitragotri, S. and J. Lahann, Physical approaches to biomaterial design. Nat 
Mater, 2009. 8(1): p. 15-23. 
91. Fahmy, T.M., et al., Inflammasome-activating nanoparticles as modular systems 
for optimizing vaccine efficacy. Vaccine, 2009. 27(23): p. 3013-3021. 
 117 
92. Ahsan, F., et al., Targeting to macrophages: role of physicochemical properties of 
particulate carriers--liposomes and microspheres--on the phagocytosis by 
macrophages. J Control Release, 2002. 79(1-3): p. 29-40. 
93. Zhang, Y., A.D. Hoppe, and J.A. Swanson, Coordination of Fc receptor signaling 
regulates cellular commitment to phagocytosis. Proceedings of the National 
Academy of Sciences of the United States of America, 2010. 107(45): p. 19332-7. 
94. Blanchette, C.D., et al., Decoupling internalization, acidification and 
phagosomal-endosomal/lysosomal fusion during phagocytosis of InlA coated 
beads in epithelial cells. PloS one, 2009. 4(6): p. e6056. 
95. Decuzzi, P. and M. Ferrari, The role of specific and non-specific interactions in 
receptor-mediated endocytosis of nanoparticles. Biomaterials, 2007. 28(18): p. 
2915-2922. 
96. Zhang, S.L., et al., Size-Dependent Endocytosis of Nanoparticles. Advanced 
Materials, 2009. 21(4): p. 419-+. 
97. Yue, T.T. and X.R. Zhang, Molecular understanding of receptor-mediated 
membrane responses to ligand-coated nanoparticles. Soft Matter, 2011. 7(19): p. 
9104-9112. 
98. Herant, M., et al., Protrusive Push versus Enveloping Embrace: Computational 
Model of Phagocytosis Predicts Key Regulatory Role of Cytoskeletal Membrane 
Anchors. Plos Computational Biology, 2011. 7(1). 
99. Gao, H.J., W.D. Shi, and L.B. Freund, Mechanics of receptor-mediated 
endocytosis. Proceedings of the National Academy of Sciences of the United 
States of America, 2005. 102(27): p. 9469-9474. 
100. Herant, M., V. Heinrich, and M. Dembo, Mechanics of neutrophil phagocytosis: 
experiments and quantitative models. Journal of Cell Science, 2006. 119(9): p. 
1903-1913. 
101. Zhang, X., R. Goncalves, and D.M. Mosser, The isolation and characterization of 
murine macrophages. Current protocols in immunology / edited by John E. 
Coligan ... [et al.], 2008. Chapter 14: p. Unit 14 1. 
102. Weischenfeldt, J. and B. Porse, Bone Marrow-Derived Macrophages (BMM): 
Isolation and Applications. CSH protocols, 2008. 2008: p. pdb prot5080. 
103. Steinkamp, J.A., et al., Phagocytosis: flow cytometric quantitation with 
fluorescent microspheres. Science, 1982. 215(4528): p. 64-6. 
104. Mammen, M., S.K. Choi, and G.M. Whitesides, Polyvalent interactions in 
biological systems: Implications for design and use of multivalent ligands and 
inhibitors. Angewandte Chemie-International Edition, 1998. 37(20): p. 2755-
2794. 
105. Tabata, Y. and Y. Ikada, Effect of the Size and Surface-Charge of Polymer 
Microspheres on Their Phagocytosis by Macrophage. Biomaterials, 1988. 9(4): p. 
356-362. 
106. Kobzik, L., Lung Macrophage Uptake of Unopsonized Environmental 
Particulates - Role of Scavenger-Type Receptors. Journal of Immunology, 1995. 
155(1): p. 367-376. 
107. Palecanda, A., et al., Role of the scavenger receptor MARCO in alveolar 
macrophage binding of unopsonized environmental particles. Journal of 
Experimental Medicine, 1999. 189(9): p. 1497-1506. 
 118 
108. Cox, D., et al., A requirement for phosphatidylinositol 3-kinase in pseudopod 
extension. The Journal of biological chemistry, 1999. 274(3): p. 1240-7. 
109. Cox, D., et al., A regulatory role for Src homology 2 domain-containing inositol 
5'-phosphatase (SHIP) in phagocytosis mediated by Fc gamma receptors and 
complement receptor 3 (alpha(M)beta(2); CD11b/CD18). The Journal of 
experimental medicine, 2001. 193(1): p. 61-71. 
110. Dietrich, G., et al., Delivery of antigen-encoding plasmid DNA into the cytosol of 
macrophages by attenuated suicide Listeria monocytogenes. Nature 
biotechnology, 1998. 16(2): p. 181-185. 
111. Whitacre, C.C., Sex differences in autoimmune disease. Nature immunology, 
2001. 2(9): p. 777-80. 
112. Heinrich, V. and C.Y. Lee, Blurred line between chemotactic chase and 
phagocytic consumption: an immunophysical single-cell perspective. Journal of 
Cell Science, 2011. 124(18): p. 3041-3051. 
113. Moghimi, S.M., et al., Material properties in complement activation. Advanced 
drug delivery reviews, 2011. 63(12): p. 1000-7. 
114. Szebeni, J., et al., Activation of complement by therapeutic liposomes and other 
lipid excipient-based therapeutic products: prediction and prevention. Advanced 
drug delivery reviews, 2011. 63(12): p. 1020-30. 
115. Porter, R.R. and K.B. Reid, Activation of the complement system by antibody-
antigen complexes: the classical pathway. Advances in protein chemistry, 1979. 
33: p. 1-71. 
116. Schumaker, V.N., P. Zavodszky, and P.H. Poon, Activation of the first component 
of complement. Annual Review of Immunology, 1987. 5: p. 21-42. 
117. Duncan, A.R. and G. Winter, The Binding-Site for Clq on Igg. Nature, 1988. 
332(6166): p. 738-740. 
118. Molina, H., et al., Markedly impaired humoral immune response in mice deficient 
in complement receptors 1 and 2. Proceedings of the National Academy of 
Sciences of the United States of America, 1996. 93(8): p. 3357-3361. 
119. Demento, S.L., et al., Inflammasome-activating nanoparticles as modular systems 
for optimizing vaccine efficacy. Vaccine, 2009. 27(23): p. 3013-3021. 
120. Al-Hanbali, O., et al., Concentration dependent structural ordering of poloxamine 
908 on polystyrene nanoparticles and their modulatory role on complement 
consumption. J Nanosci Nanotechnol, 2006. 6(9-10): p. 3126-33. 
121. Moghimi, S.M., et al., Causative factors behind poloxamer 188 (Pluronic F68, 
Flocor)-induced complement activation in human sera. A protective role against 
poloxamer-mediated complement activation by elevated serum lipoprotein levels. 
Biochimica et biophysica acta, 2004. 1689(2): p. 103-13. 
122. Vonarbourg, A., et al., Parameters influencing the stealthiness of colloidal drug 
delivery systems. Biomaterials, 2006. 27(24): p. 4356-73. 
123. Ahsan, F.L., et al., Targeting to macrophages: role of physicochemical properties 
of particulate carriers-liposomes and microspheres-on the phagocytosis by 
macrophages. Journal of Controlled Release, 2002. 79(1-3): p. 29-40. 
124. Vorup-Jensen, T., On the roles of polyvalent binding in immune recognition: 
Perspectives in the nanoscience of immunology and the immune response to 
nanomedicines. Advanced drug delivery reviews, 2012. 64(15): p. 1759-81. 
 119 
125. Devine, D.V., et al., Liposome-Complement Interactions in Rat Serum - 
Implications for Liposome Survival Studies. Biochimica Et Biophysica Acta-
Biomembranes, 1994. 1191(1): p. 43-51. 
126. Pedersen, M.B., et al., Curvature of synthetic and natural surfaces is an important 
target feature in classical pathway complement activation. Journal of 
Immunology, 2010. 184(4): p. 1931-45. 
127. Harashima, H., et al., Synergistic effect between size and cholesterol content in 
the enhanced hepatic uptake clearance of liposomes through complement 
activation in rats. Pharmaceutical research, 1996. 13(11): p. 1704-1709. 
128. Burton, D.R., Immunoglobulin G: functional sites. Molecular immunology, 1985. 
22(3): p. 161-206. 
129. Wright, J.K., et al., Dimeric, trimeric and tetrameric complexes of 
immunoglobulin G fix complement. The Biochemical journal, 1980. 187(3): p. 
775-80. 
130. Lambris, J.D., K.B. Reid, and J.E. Volanakis, The evolution, structure, biology 
and pathophysiology of complement. Immunology today, 1999. 20(5): p. 207-11. 
131. Flierl, M.A., et al., Complement C3 serum levels in anorexia nervosa: a potential 
biomarker for the severity of disease? Annals of general psychiatry, 2011. 10: p. 
16. 
132. Seregin, S.S., et al., Novel Adenovirus Vectors 'Capsid-Displaying' a Human 
Complement Inhibitor. Journal of Innate Immunity, 2010. 2(4): p. 353-359. 
133. Busch, N.A., M.S. Wertheim, and M.L. Yarmush, Monte Carlo simulation of n-
member associating fluids: Application to antigen-antibody systems. Journal of 
Chemical Physics, 1996. 104(11): p. 3962-3975. 
134. Gemmell, C.H., A flow cytometric immunoassay to quantify adsorption of 
complement activation products (iC3b, C3d, SC5b-9) on artificial surfaces. J 
Biomed Mater Res, 1997. 37(4): p. 474-80. 
135. Armstrong, J.K., et al., The hydrodynamic radii of macromolecules and their 
effect on red blood cell aggregation. Biophysical journal, 2004. 87(6): p. 4259-
4270. 
136. Murphy, R.M., et al., Size and Structure of Antigen-Antibody Complexes - 
Electron-Microscopy and Light-Scattering Studies. Biophysical journal, 1988. 
54(1): p. 45-56. 
137. Ban, N., et al., Crystal-Structure of an Idiotype Antiidiotype Fab Complex. 
Proceedings of the National Academy of Sciences of the United States of 
America, 1994. 91(5): p. 1604-1608. 
138. Werner, T.C., J.R. Bunting, and R.E. Cathou, The shape of immunoglobulin G 
molecules in solution. Proceedings of the National Academy of Sciences of the 
United States of America, 1972. 69(4): p. 795-9. 
139. Schneider, S. and M. Zacharias, Atomic resolution model of the antibody Fc 
interaction with the complement C1q component. Molecular immunology, 2012. 
51(1): p. 66-72. 
140. Henry, N., J.W. Parce, and H.M. McConnell, Visualization of specific antibody 
and C1q binding to hapten-sensitized lipid vesicles. Proceedings of the National 
Academy of Sciences of the United States of America, 1978. 75(8): p. 3933-7. 
 120 
141. Parce, J.W., N. Henry, and H.M. McConnell, Specific antibody-dependent binding 
of complement component C1q to hapten-sensitized lipid vesicles. Proceedings of 
the National Academy of Sciences of the United States of America, 1978. 75(3): 
p. 1515-8. 
142. Hughesjones, N.C. and B. Gardner, Reaction between the Isolation Globular 
Subunits of the Complement Component Clq and Igg-Complexes. Molecular 
immunology, 1979. 16(9): p. 697-701. 
143. Taylor, P.W., Bactericidal and Bacteriolytic Activity of Serum against Gram-
Negative Bacteria. Microbiological Reviews, 1983. 47(1): p. 46-83. 
144. Aldwell, F.E., et al., Oral vaccination of mice with lipid-encapsulated 
Mycobacterium bovis BCG: Anatomical sites of bacterial replication and immune 
activity. Immunology and Cell Biology, 2005. 83(5): p. 549-553. 
145. Aldwell, F.E., et al., Oral delivery of lipid-encapsulated Mycobacterium bovis 
BCG extends survival of the bacillus in vivo and induces a long-term protective 
immune response against tuberculosis. Vaccine, 2006. 24(12): p. 2071-2078. 
146. Giri, P.K., et al., Comparative evaluation of intranasal and subcutaneous route of 
immunization for development of mucosal vaccine against experimental 
tuberculosis. Fems Immunology and Medical Microbiology, 2005. 45(1): p. 87-
93. 
147. Griffiths, G., et al., Nanobead-based interventions for the treatment and 
prevention of tuberculosis. Nature Reviews Microbiology, 2010. 8(11): p. 827-
834. 
148. Hiraishi, Y., et al., Bacillus Calmette-Guerin vaccination using a microneedle 
patch. Vaccine, 2011. 29(14): p. 2626-2636. 
149. Pacheco, P., D. White, and T. Sulchek, Effects of microparticle size and Fc 
density on macrophage phagocytosis. PLoS One, 2013. 8(4): p. e60989. 
150. Pacheco, P.M., et al., TUNABLE COMPLEMENT ACTIVATION BY PARTICLES 
WITH VARIABLE SIZE AND Fc DENSITY. Nano Life, 2013. 3(2): p. 1341001. 
151. Maglione, P.J., et al., Fc gamma receptors regulate immune activation and 
susceptibility during Mycobacterium tuberculosis infection. J Immunol, 2008. 
180(5): p. 3329-38. 
152. Clemens, D.L. and M.A. Horwitz, Characterization of the Mycobacterium 
tuberculosis phagosome and evidence that phagosomal maturation is inhibited. J 
Exp Med, 1995. 181(1): p. 257-70. 
153. Nozaki, Y., et al., Mechanism of nitric oxide-dependent killing of Mycobacterium 
bovis BCG in human alveolar macrophages. Infect Immun, 1997. 65(9): p. 3644-
7. 
154. Schaible, U.E., et al., Cytokine activation leads to acidification and increases 
maturation of Mycobacterium avium-containing phagosomes in murine 
macrophages. J Immunol, 1998. 160(3): p. 1290-6. 
 
 
